99 results on '"Jeanette Pullen"'
Search Results
2. Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
- Author
-
Jitsuda Sitthi-amorn, Betty Herrington, Gail Megason, Jeanette Pullen, Catherine Gordon, Shirley Hogan, Tejaswi Koganti, and Chindo Hicks
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2015
3. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children’s Oncology Group Studies P9904 and P9905
- Author
-
Paul L. Martin, William L. Carroll, Bruce M. Camitta, Michael J. Borowitz, W. Paul Bowman, Jonathan J. Shuster, Stephen P. Hunger, Jeanette Pullen, Cheryl L. Willman, Meenakshi Devidas, Naomi J. Winick, Andrew J. Carroll, and Eric Larsen
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,Neoplasm, Residual ,Time Factors ,Dexamethasone ,Random Allocation ,0302 clinical medicine ,Prednisone ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Mercaptopurine ,Drug Administration Routes ,Remission Induction ,Cytarabine ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Treatment Outcome ,Childhood B-ALL ,Vincristine ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,medicine.medical_specialty ,Randomization ,Adolescent ,Article ,Drug Administration Schedule ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Overall survival ,Asparaginase ,Humans ,Cyclophosphamide ,business.industry ,Daunorubicin ,Infant ,Cancer ,medicine.disease ,Survival Analysis ,Minimal residual disease ,Methotrexate ,030104 developmental biology ,business - Abstract
The delayed intensification (DI) enhanced outcome for patients with acute lymphoblastic leukemia (ALL) treated on BFM 76/79 and CCG 105 after a prednisone-based induction. Childrens Oncology Group protocols P9904/9905 evaluated DI via a post-induction randomization for eligible National Cancer Institute (NCI) standard (SR) and high-risk (HR) patients. A second randomization compared intravenous methotrexate (IV MTX) as a 24- (1 g/m(2)) vs. 4-h (2 g/m(2)) infusion. NCI SR patients received a dexamethasone-based three-drug and NCI HR/CNS 3 SR patients a prednisone-based four-drug induction. End induction MRD (minimal residual disease) was obtained but did not impact treatment. DI improved the 10-year continuous complete remission (CCR) rate; 75.5 ± 2.5% vs. 81.8 ± 2.2% p = 0.002, whereas MTX administration did not; 4-h 80.8 ± 1.9%; 24-h 81.4 ± 1.9% (p = 0.7780). Overall survival (OS) at 10 years did not differ with DI: 91.4 ± 1.6% vs. 90.9 ± 1.7% (p = 0.25) without but was higher with the 24-h MTX infusion; 4-h 91.1 ± 1.4%; 24-h 93.9 ± 1.2% (p = 0.0209). MRD predicted outcome; 10-year CCR 87.7 ± 2.2 and 82.1 ± 2.5% when MRD was
- Published
- 2019
4. Dose Intensification of Methotrexate and Cytarabine During Intensified Continuation Chemotherapy for High-risk B-Precursor Acute Lymphoblastic Leukemia
- Author
-
Naomi J. Winick, Joanne Kurtzberg, Bruce M. Camitta, Beverly Bell, Edward C. Halperin, Jeanette Pullen, Tamekia L. Jones, Jonathan J. Shuster, Barbara L. Asselin, Allen R. Chauvenet, Richard L. Tower, and Meenakshi Devidas
- Subjects
Male ,Oncology ,Asparaginase ,medicine.medical_specialty ,medicine.medical_treatment ,Article ,law.invention ,chemistry.chemical_compound ,Randomized controlled trial ,Risk Factors ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Child ,Survival rate ,Teniposide ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Remission Induction ,Cytarabine ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Survival Rate ,Methotrexate ,chemistry ,Pediatrics, Perinatology and Child Health ,Toxicity ,Female ,business ,Follow-Up Studies ,medicine.drug - Abstract
To determine the efficacy and toxicity of higher dose versus standard dose intravenous methotrexate (MTX) and pulses of high-dose cytosine arabinoside with asparaginase versus standard dose cytosine arabinoside and teniposide during intensified continuation therapy for higher risk pediatric B-precursor acute lymphoblastic leukemia (ALL).From 1994 to 1999, the Pediatric Oncology Group conducted a randomized phase III clinical trial in higher risk pediatric B-precursor ALL. A total of 784 patients were randomized in a 2×2 factorial design to receive MTX 1 g/m versus 2.5 g/m and to cytosine arabinoside/teniposide versus high-dose cytosine arabinoside/asparaginase during intensified continuation therapy.Patients receiving standard dose MTX had a 5-year disease-free survival (DFS) of 71.8±2.4%; patients receiving higher dose MTX had a 5-year DFS of 71.7±2.4% (P=0.55). Outcomes on cytosine arabinoside/teniposide (DFS of 70.4±2.4) were similar to higher dose cytosine arabinoside/asparaginase (DFS of 73.1±2.3%) (P=0.41). Overall survival rates were not different between MTX doses or cytosine arabinoside/teniposide versus cytosine arabinoside/asparaginase.Increasing MTX dosing to 2.5 g/m did not improve outcomes in higher risk pediatric B-precursor ALL. Giving high-dose cytarabine and asparaginase pulses instead of standard dose cytarabine and teniposide produced nonsignificant differences in outcomes, allowing for teniposide to be removed from ALL therapy.
- Published
- 2014
5. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study
- Author
-
Cheryl L. Willman, Huining Kang, I-Ming Chen, Bruce M. Camitta, Stephen P. Hunger, Julie M. Gastier-Foster, Richard C. Harvey, Debbie Payne-Turner, Catherine E. Cottrell, Andrew J. Carroll, Mignon L. Loh, Naomi J. Winick, Meenakshi Devidas, Walker Wharton, Gregory H. Reaman, Michael J. Borowitz, Shalini C. Reshmi, Sarah K. Tasian, W. Paul Bowman, William L. Carroll, Charles G. Mullighan, and D. Jeanette Pullen
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,Multivariate analysis ,Adolescent ,Clinical Trials and Observations ,Immunology ,Medical Oncology ,medicine.disease_cause ,Biochemistry ,Ikaros Transcription Factor ,Cog ,Pediatric Acute Lymphoblastic Leukemia ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Receptors, Cytokine ,Child ,Interleukin-7 receptor ,Gene ,Societies, Medical ,Janus Kinases ,Clinical Trials as Topic ,Mutation ,Models, Statistical ,business.industry ,Infant ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Survival Analysis ,Minimal residual disease ,Treatment Outcome ,Child, Preschool ,Cohort ,Female ,business - Abstract
As controversy exists regarding the prognostic significance of genomic rearrangements of CRLF2 in pediatric B-precursor acute lymphoblastic leukemia (ALL) classified as standard/intermediate-risk (SR) or high-risk (HR), we assessed the prognostic significance of CRLF2 mRNA expression, CRLF2 genomic lesions (IGH@-CRLF2, P2RY8-CRLF2, CRLF2 F232C), deletion/mutation in genes frequently associated with high CRLF2 expression (IKZF1, JAK, IL7R), and minimal residual disease (MRD) in 1061 pediatric ALL patients (499 HR and 562 SR) on COG Trials P9905/P9906. Whereas very high CRLF2 expression was found in 17.5% of cases, only 51.4% of high CRLF2 expressors had CRLF2 genomic lesions. The mechanism underlying elevated CRLF2 expression in cases lacking known genomic lesions remains to be determined. All CRLF2 genomic lesions and virtually all JAK mutations were found in high CRLF2 expressors, whereas IKZF1 deletions/mutations were distributed across the full cohort. In multivariate analyses, NCI risk group, MRD, high CRLF2 expression, and IKZF1 lesions were associated with relapse-free survival. Within HR ALL, only MRD and CRLF2 expression predicted a poorer relapse-free survival; no difference was seen between cases with or without CRLF2 genomic lesions. Thus, high CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, ALL. This study is registered at www.clinicaltrials.gov as NCT00005596 and NCT00005603.
- Published
- 2012
6. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404
- Author
-
Jeanette Pullen, Yaddanapudi Ravindranath, Vivian I. Franco, Robert E. Hutchison, Lu Chen, Steven E. Lipshultz, Meenakshi Devidas, Barbara L. Asselin, Michael J. Borowitz, Bruce M. Camitta, and Saro H. Armenian
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Cardiotonic Agents ,medicine.medical_treatment ,030204 cardiovascular system & hematology ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Troponin T ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Doxorubicin ,Dexrazoxane ,Child ,Chemotherapy ,Cardiotoxicity ,Errata ,Random assignment ,business.industry ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Lymphoma ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,business ,Cardiomyopathies ,medicine.drug - Abstract
Purpose To determine the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin dose of 360 mg/m2 to treat children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic non-Hodgkin lymphoma (L-NHL). Patients and Methods Patients were treated on Pediatric Oncology Group Protocol POG 9404, which included random assignment to treatment with or without dexrazoxane given as a bolus infusion immediately before every dose of doxorubicin. Cardiac effects were assessed by echocardiographic measurements of left ventricular function and structure. Results Of 573 enrolled patients, 537 were eligible, evaluable, and randomly assigned to an arm with or without dexrazoxane. The 5-year event-free survival (with standard error) did not differ between groups: 77.2% (2.7%) for the dexrazoxane group versus 76.0% (2.7%) for the doxorubicin-only group (P = .9). The frequencies of severe grade 3 or 4 hematologic toxicity, infection, CNS events, and toxic deaths were similar in both groups (P ranged from .26 to .64). Of 11 second malignancies, eight occurred in patients who received dexrazoxane (P = .17). The mean left ventricular fractional shortening, wall thickness, and thickness-to-dimension ratio z scores measured 3 years after diagnosis were worse in the doxorubicin-alone group (n = 79-84 per group; P ≤ .01 for all comparisons). Mean fractional shortening z scores measured 3.5 to 6.4 years after diagnosis remained diminished and were lower in the 21 patients who received doxorubicin alone than in the 31 patients who received dexrazoxane (−2.03 v −0.24; P ≤ .001). Conclusion Dexrazoxane was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of toxicities, and was not associated with a significant increase in second malignancies with this doxorubicin-containing chemotherapy regimen. We recommend dexrazoxane as a cardioprotectant for children and adolescents who have malignancies treated with anthracyclines.
- Published
- 2015
7. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404)
- Author
-
Jeanette Pullen, Robert E. Hutchison, Steven E. Lipshultz, Bruce M. Camitta, Michael J. Borowitz, Chenguang Wang, Barbara L. Asselin, and Meenakshi Devidas
- Subjects
Male ,Mucositis ,medicine.medical_specialty ,Pediatrics ,Randomization ,Adolescent ,medicine.medical_treatment ,Immunology ,Antineoplastic Agents ,Biochemistry ,Gastroenterology ,Disease-Free Survival ,law.invention ,Young Adult ,Randomized controlled trial ,law ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Young adult ,Child ,Proportional Hazards Models ,Chemotherapy ,business.industry ,Lymphoblastic lymphoma ,Infant ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,medicine.disease ,Chemotherapy regimen ,Methotrexate ,Child, Preschool ,Female ,business ,medicine.drug - Abstract
The Pediatric Oncology Group (POG) phase 3 trial 9404 was designed to determine the effectiveness of high-dose methotrexate (HDM) when added to multi-agent chemotherapy based on the Dana-Farber backbone. Children with T-cell acute lymphoblastic leukemia (T-ALL) or advanced lymphoblastic lymphoma (T-NHL) were randomized at diagnosis to receive/not receive HDM (5 g/m2 as a 24-hour infusion) at weeks 4, 7, 10, and 13. Between 1996 and 2000, 436 patients were enrolled in the methotrexate randomization. Five-year and 10-year event-free survival (EFS) was 80.2% ± 2.8% and 78.1% ± 4.3% for HDM (n = 219) versus 73.6% ± 3.1% and 72.6% ± 5.0% for no HDM (n = 217; P = .17). For T-ALL, 5-year and 10-year EFS was significantly better with HDM (n = 148, 5 years: 79.5% ± 3.4%, 10 years: 77.3% ± 5.3%) versus no HDM (n = 151, 5 years: 67.5% ± 3.9%, 10 years: 66.0% ± 6.6%; P = .047). The difference in EFS between HDM and no HDM was not significant for T-NHL patients (n = 71, 5 years: 81.7% ± 4.9%, 10 years: 79.9% ± 7.5% vs n = 66, 5 years: 87.8% ± 4.2%, 10 years: 87.8% ± 6.4%; P = .38). The frequency of mucositis was significantly higher in patients treated with HDM (P = .003). The results support adding HDM to the treatment of children with T-ALL, but not with NHL, despite the increased risk of mucositis.
- Published
- 2011
8. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906
- Author
-
D. Jeanette Pullen, Cheryl L. Willman, William L. Carroll, Naomi J. Winick, W. Paul Bowman, Laurie Blach, Andrew J. Carroll, Stephen B. Linda, Michael J. Borowitz, Stephen P. Hunger, Eric Larsen, Jonathan J. Shuster, Meenakshi Devidas, and Bruce M. Camitta
- Subjects
Oncology ,Group trial ,medicine.medical_specialty ,business.industry ,Lymphoblastic Leukemia ,Hematology ,medicine.disease ,Minimal residual disease ,Regimen ,medicine.anatomical_structure ,Patient age ,Acute lymphocytic leukemia ,White blood cell ,Internal medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Pediatric oncology ,business - Abstract
Background—The augmented BFM regimen improves outcome for children with NCI high acute lymphoblastic leukemia (ALL). Patient age, sex, and presenting white blood cell count (WBC) can be used to identify a subset of approximately 12% of children with B-precursor ALL that had a 5-year continuous complete remission (CCR) rate of only about 50% on earlier Pediatric Oncology Group (POG) trials. Procedures—Children’s Oncology Group trial P9906 evaluated a modified augmented BFM regimen in 267 patients with particularly high risk B-precursor ALL. Minimal residual disease (MRD) was assessed in blood at day 8 and in marrow at day 29 of Induction and correlated with outcome.
- Published
- 2011
9. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group
- Author
-
Paul L. Martin, Cheryl L. Willman, Stephen P. Hunger, Jeanette Pullen, Michael J. Borowitz, Meenakshi Devidas, Kelly W. Maloney, Bruce M. Camitta, Naomi J. Winick, James A. Whitlock, William L. Carroll, and Andrew J. Carroll
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Down syndrome ,Neoplasm, Residual ,Oncogene Proteins, Fusion ,Immunology ,Fusion Proteins, bcr-abl ,Aneuploidy ,Trisomy ,Biology ,Polymerase Chain Reaction ,Biochemistry ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,Internal medicine ,White blood cell ,medicine ,Humans ,Prospective Studies ,Child ,Prospective cohort study ,Childhood Acute Lymphoblastic Leukemia ,Survival rate ,Chromosome Aberrations ,Hematology ,Chromosomes, Human, Pair 10 ,Histone-Lysine N-Methyltransferase ,Cell Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Survival Rate ,Treatment Outcome ,medicine.anatomical_structure ,Core Binding Factor Alpha 2 Subunit ,Female ,Chromosomes, Human, Pair 4 ,Down Syndrome ,Myeloid-Lymphoid Leukemia Protein - Abstract
Children with Down syndrome (DS) have an increased risk of acute lymphoblastic leukemia (ALL) and an inferior outcome. We reviewed data from 2811 children with ALL enrolled in Children's Oncology Group P9900, which included prospective testing for the major cytogenetic lesions in childhood ALL: ETV6-RUNX1, TCF3-PBX1, BCR-ABL1, and MLL translocations and trisomies of chromosomes 4 and 10. Eighty (3%) B-precursor ALL patients had DS. Age, sex, white blood cell count, and risk group were similar between DS-ALL and non–DS-ALL but significantly more patients with DS-ALL were white (91.2% vs 76.4%, P = .001). Children with DS-ALL had lower rates of the favorable cytogenetic lesions ETV6-RUNX1 (2.5% vs 24%, P < .001) and trisomies 4 and 10 (7.7% vs 24%, P < .001). Five-year event-free (EFS) and overall survival (OS) were inferior in children with DS-ALL: 69.9% ± 8.6% versus 78.1% ± 1.2% (P = .078), and 85.8% ± 6.5% versus 90.0% ± 0.9% (P = .033). However, when children with MLL translocations, BCR-ABL1, ETV6-RUNX1, and trisomies 4 and 10 were excluded, the EFS and OS were similar for children with and without DS (EFS 68.0 %± 9.3% vs 70.5% ± 1.9%, P = .817; and OS 86.7% ± 6.7% vs 85.4% ± 1.5%; P = .852), both overall and adjusted for race. DS-ALL displays a unique spectrum of biologic subtypes with different frequencies of sentinel cytogenetic lesions having a large influence on outcome.
- Published
- 2010
10. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group
- Author
-
Stephen P. Hunger, Meenakshi Devidas, Naomi J. Winick, Jeanette Pullen, Wanda L. Salzer, Bruce M. Camitta, and William L. Carroll
- Subjects
Male ,Infant ALL ,Oncology ,Cancer Research ,Neoplasm, Residual ,Time Factors ,medicine.medical_treatment ,chemistry.chemical_compound ,0302 clinical medicine ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,Child ,Outcome ,0303 health sciences ,Acute leukemia ,T-lineage ALL ,Remission Induction ,Neoplasms, Second Primary ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Combined Modality Therapy ,3. Good health ,Survival Rate ,Treatment Outcome ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,medicine.drug ,Adult ,medicine.medical_specialty ,Asparaginase ,Adolescent ,Prognostic factors ,Article ,Immunophenotyping ,B-lineage ALL ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Childhood Acute Lymphoblastic Leukemia ,Survival rate ,030304 developmental biology ,Chromosome Aberrations ,Chemotherapy ,business.industry ,Infant ,Mercaptopurine ,chemistry ,Methotrexate ,Cranial Irradiation ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies ,Teniposide - Abstract
From 1984 to 2001, the Pediatric Oncology Group (POG) conducted 12 acute lymphoblastic leukemia (ALL) studies. Ten-year event-free survival (EFS) for patients >12 months of age with B-precursor ALL on acute leukemia in children 14, 15 and 16 series were 66.7+/-1.2%, 68.1+/-1.4% and 73.2+/-2.1%, respectively. Intermediate dose methotrexate (ID MTX; 1 g/m(2)) improved outcomes for standard risk patients (10-year EFS 77.5+/-2.7% vs 66.3+/-3.1% for oral MTX). Neither MTX intensification (2.5 g/m(2)) nor addition of cytosine arabinoside/daunomycin/teniposide improved outcomes for higher risk patients. Intermediate dose mercaptopurine (1 g/m(2)) failed to improve outcomes for either group. Ten-year EFS for patients with T-cell ALL, POG 8704 and 9404 were 49.1+/-3.1% and 72.2+/-4.7%, respectively. Intensive asparaginase (10-year EFS 61.8 vs 42.7%) and high-dose MTX (5 g/m(2)) (10-year EFS 78.0 vs 65.8%) improved outcomes. There was a non-significant improvement in EFS for infants (10-year EFS 17.7+/-7.2-31.9+/-8.3%). Prognostic indicators for B-precursor ALL were age and WBC at diagnosis, gender, central nervous system disease, DNA index and cytogenetic abnormalities. Only gender was prognostic in T-cell ALL. In infants, WBC and MLL translocation were linked to inferior outcome.
- Published
- 2009
11. Allergic Reactions to E. coli L-Asparaginase Do Not Affect Outcome in Childhood B-precursor Acute Lymphoblastic Leukemia
- Author
-
Pierre Wacker, Jeanette Pullen, Jonathan J. Shuster, Michael E. Harris, Vita J. Land, Joanne Kurtzberg, and Bruce M. Camitta
- Subjects
Adult ,Male ,Allergy ,medicine.medical_specialty ,Adolescent ,Lymphoblastic Leukemia ,Erwinia ,medicine.disease_cause ,Gastroenterology ,law.invention ,L asparaginase ,Bacterial Proteins ,Randomized controlled trial ,law ,Asparaginase/adverse effects/immunology/therapeutic use ,Internal medicine ,Escherichia coli ,Hypersensitivity ,medicine ,Asparaginase ,Humans ,Escherichia coli/enzymology ,Child ,ddc:618 ,biology ,Group study ,business.industry ,Infant ,Hematology ,biology.organism_classification ,medicine.disease ,Burkitt Lymphoma ,Bacterial Proteins/adverse effects/immunology/therapeutic use ,Regimen ,Treatment Outcome ,Oncology ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Immunology ,Erwinia/enzymology ,business ,Burkitt Lymphoma/drug therapy ,Hypersensitivity/immunology - Abstract
We describe the outcome of children with B-precursor acute lymphoblastic leukemia registered on Pediatric Oncology Group 8602 who switched to Erwinia asparaginase (ASP) due to an allergy to the Escherichia coli product. Between February 1986 and January 1991, children in complete remission after induction that included intramuscular E. coli ASP (6000 U/m2x6) were randomized for consolidation. One regimen included intensive weekly intramuscular E. coli ASP (25,000 U/m2/wkx24). In case of an allergic reaction to E. coli ASP, Erwinia ASP was substituted at the same dose and schedule. Of the 540 eligible patients, 408 switched to Erwinia ASP due to an allergic reaction. Allergic reactions were significantly associated with younger age, white race, and standard-risk acute lymphoblastic leukemia. Multivariate Cox analysis adjusting for these factors demonstrated no correlation between the switch per se or the timing of the switch and event-free survival.
- Published
- 2007
12. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201
- Author
-
Jonathan J. Shuster, Jeanette Pullen, Meenakshi Devidas, Paul L. Martin, Mark J. Pettenati, Bruce M. Camitta, Beverly Bell, Joanne Kurtzberg, Andrew J. Carroll, Stephen B. Linda, and Allen R. Chauvenet
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Vincristine ,Asparaginase ,Immunology ,Pilot Projects ,Injections, Intramuscular ,Biochemistry ,Disease-Free Survival ,Central Nervous System Neoplasms ,chemistry.chemical_compound ,Prednisone ,Internal medicine ,Acute lymphocytic leukemia ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Cell Lineage ,Child ,Infusions, Intravenous ,Injections, Spinal ,B-Lymphocytes ,Acute leukemia ,Mercaptopurine ,business.industry ,Remission Induction ,Infant ,Cell Biology ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Leukemia ,Methotrexate ,Treatment Outcome ,chemistry ,Child, Preschool ,Female ,business ,medicine.drug - Abstract
Pediatric Oncology Group (POG) protocol 9201 enrolled children with lesser-risk B-lineage acute lymphoblastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 × 109/L (50 000/μL), DNA findings of trisomies 4 and 10 (or DNA index > 1.16), and lack of overt central nervous system (CNS) leukemia. After vincristine, prednisone, and asparaginase induction, 650 of 653 eligible patients attained remission (3 induction deaths) and received 6 courses of intravenous methotrexate (1 g/m2) with daily mercaptopurine. Weekly intramuscular methotrexate was added during maintenance; pulses of vincristine and prednisone were administered with periodic intrathecal chemotherapy. Treatment duration was 2.5 years. No alkylators, epipodophylotoxins, anthracyclines, or radiation were given. The 6-year event-free survival (EFS) was 86.6% with overall survival (OS) of 97.2%. Patients with less than 5% marrow blasts on induction day 15 had superior EFS. A difference not reaching conventional statistical significance (P = .068) was noted for superior outcomes in patients with trisomies of chromosomes 4 and 10 versus those lacking double trisomies. Sex, ethnicity, CNS status, and WBC were not predictive. This indicates the great majority of children with lesser-risk B-lineage ALL are curable without agents with substantial late effects.
- Published
- 2007
13. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors
- Author
-
Lisa Bomgaars, Susan M. Blaney, Steve Dale Weitman, Linda Hershon, Gail Megason, John G. Kuhn, Jeanette Pullen, Mark Bernstein, and Anne-Marie R Langevin
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Drug-Related Side Effects and Adverse Reactions ,Maximum Tolerated Dose ,Hyperkalemia ,Gastroenterology ,Drug Administration Schedule ,Ondansetron ,chemistry.chemical_compound ,Refractory ,Pharmacokinetics ,Neoplasms ,Internal medicine ,medicine ,Humans ,Irofulven ,Child ,Antineoplastic Agents, Alkylating ,Dexamethasone ,business.industry ,Hematology ,Surgery ,Oncology ,chemistry ,Child, Preschool ,Concomitant ,Pediatrics, Perinatology and Child Health ,Toxicity ,Female ,medicine.symptom ,business ,Sesquiterpenes ,medicine.drug - Abstract
Purpose We performed a Phase I trial of irofulven (MGI 114) to determine the maximum tolerated dose (MTD), the dose-limiting toxicity (DLT), and the plasma pharmacokinetics of irofulven in children ≤21 years of age with refractory/recurrent malignancies. Experimental Design Thirty-five patients were entered into the study, of whom 34 were eligible. Patients received Irofulven daily × 5 days every 28 days over 10 min, following pre-treatment with ondansetron (0.45 mg/kg) and dexamethasone (12 mg/m2). The initial dose of irofulven was 8 mg/m2 daily, with subsequent escalations to 10, 13, and 17 mg/m2. Plasma pharmacokinetic samples were obtained in a subset patients. Results Thirty-two patients were assessable for toxicity, and 30 were assessable for response. In heavily pre-treated patients, dose-limiting thrombocytopenia was observed in two patients at the 8 mg/m2/day, and in one patient at the 6 mg/m2/day dose level. In less heavily pre-treated patients, proteinuria and elevated creatinine were dose limiting in two patients at the 17 mg/m2/day dose level. At 13 mg/m2/day, constipation, hyperkalemia with elevated creatinine, and thrombocytopenia was dose limiting in three patients. There were no complete or partial responses. One patient with poorly differentiated carcinoma had stable disease and received 11 courses of therapy. Patients demonstrated a lower systemic exposure and greater clearance than adults treated at similar dose levels. Conclusion The MTD of irofulven administered daily × 5 every 28 days with concomitant ondansetron and dexamethasone is 6 mg/m2/day in heavily pre-treated patients and 10 mg/m2/day in less heavily pre-treated patients. © 2005 Wiley-Liss, Inc.
- Published
- 2006
14. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group
- Author
-
Paul L. Martin, W. Paul Bowman, Bruce M. Camitta, Naomi J. Winick, D. Jeanette Pullen, and Michael J. Borowitz
- Subjects
Oncology ,medicine.medical_specialty ,Neoplasm, Residual ,Histology ,Population ,CD34 ,Medical Oncology ,Sensitivity and Specificity ,Pathology and Forensic Medicine ,Cohort Studies ,Recurrence ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Neoplasm ,Stage (cooking) ,Child ,education ,Childhood Acute Lymphoblastic Leukemia ,education.field_of_study ,business.industry ,Cell Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Flow Cytometry ,medicine.disease ,Minimal residual disease ,Leukemia ,Phenotype ,Treatment Outcome ,medicine.anatomical_structure ,Bone marrow ,business ,Follow-Up Studies - Abstract
Background: Flow cytometric analysis of minimal residual disease (MRD) depends on detecting phenotypically abnormal populations. However, little is known about how phenotypic shifts between diagnosis and relapse affect MRD detection in childhood acute lymphoid leukemia (ALL). Methods: We compared diagnostic and relapse bone marrow specimens in 42 children with precursor B-ALL studied with the two-tube panel CD19-APC/CD45-PerCP/CD10-PE/CD20-FITC and CD19-APC/CD45-PerCP/CD9-PE/CD34-FITC. Results: At least 29 cases had phenotypic shifts of intensity or coefficient of variation of distribution of one or more markers. Shifts were complex and could not be explained by change in maturation stage. In the majority of cases MRD populations more closely resembled the diagnostic than the relapse specimen. In 6 of 7 MRD negative cases we did not identify an abnormal population that resembled diagnosis or relapse. In the remaining case, in which CD34 and CD10 were lost between diagnosis and relapse, it is possible that we could have missed an MRD population resembling relapse. Conclusions: Phenotypic shifts are common, but do not affect MRD recognition. At most 1 of 42 cases might have harbored an abnormal population undetected because of shift. However, MRD analysis with rigid gating (looking strictly for abnormal phenotypes at diagnosis) might have missed many positive cases, 8 of 22 (36%) in this series. © 2005 Wiley-Liss, Inc.
- Published
- 2005
15. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements
- Author
-
Yinmei Zhou, Martin Schrappe, Ching-Hon Pui, Giuseppe Masera, Lewis B. Silverman, M. G. Valsecchi, William E. Evans, S Richards, Susana C. Raimondi, Nyla A. Heerema, Etienne Vilmer, Andrea Biondi, André Baruchel, Bruce M. Camitta, Jeanette Pullen, G. E. Janka-Schaub, Harland Sather, Christine J. Harrison, Jonathan J. Shuster, Stephen E. Sallan, Jochen Harbott, JM Chessells, D. Harms, Willem Kamps, Helmut Gadner, Paul S. Gaynon, Patricia L. Harrison, OB Eden, H. Riehm, James M. Boyett, Andrew J. Carroll, University of Groningen, Pui, C, Chessells, J, Camitta, B, Baruchel, A, Biondi, A, Boyett, J, Carroll, A, Eden, O, Evans, W, Gadner, H, Harbott, J, Harms, D, Harrison, C, Harrison, P, Heerema, N, Janka Schaub, G, Kamps, W, Masera, G, Pullen, J, Raimondi, S, Richards, S, Riehm, H, Sallan, S, Sather, H, Shuster, J, Silverman, L, Valsecchi, M, Vilmer, E, Zhou, Y, Gaynon, P, and Schrappe, M
- Subjects
Male ,MLL rearrangement ,Cancer Research ,Oncogene Proteins, Fusion ,Transcription Factor ,T-Lymphocytes ,medicine.medical_treatment ,FEATURES ,INFANTS ,Proto-Oncogene ,Hematopoietic stem cell transplantation ,Translocation, Genetic ,Cohort Studies ,Leukocyte Count ,11q23 ,Retrospective Studie ,Risk Factors ,Prednisone ,PEDIATRIC-ONCOLOGY-GROUP ,Antineoplastic Combined Chemotherapy Protocols ,Age Factor ,t(4 ,11) ,Young adult ,Child ,t(11 ,19) ,B-Lymphocytes ,B-Lymphocyte ,Age Factors ,Hematopoietic Stem Cell Transplantation ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Prognosis ,Combined Modality Therapy ,DNA-Binding Proteins ,Europe ,Treatment Outcome ,Oncology ,Child, Preschool ,Neoplastic Stem Cells ,Female ,Chromosomes, Human, Pair 4 ,Chromosomes, Human, Pair 9 ,TYROSINE KINASE INHIBITOR ,MLL-GENE REARRANGEMENTS ,Myeloid-Lymphoid Leukemia Protein ,P13.3) ,Human ,medicine.drug ,United State ,medicine.medical_specialty ,Adolescent ,Prognosi ,DNA-Binding Protein ,infant leukemia ,acute lymphoblastic leukemia ,Biology ,Chromosome Aberration ,Disease-Free Survival ,CHILDRENS CANCER GROUP ,AGE ,POOR-PROGNOSIS ,Acute lymphocytic leukemia ,Internal medicine ,Proto-Oncogenes ,medicine ,Humans ,T(11/19)(Q23 ,Childhood Acute Lymphoblastic Leukemia ,Proportional Hazards Models ,Retrospective Studies ,Chromosome Aberrations ,Antineoplastic Combined Chemotherapy Protocol ,Proportional hazards model ,Risk Factor ,Chromosomes, Human, Pair 11 ,Infant ,Histone-Lysine N-Methyltransferase ,Gene rearrangement ,IN-VITRO ,medicine.disease ,United States ,Transplantation ,T-Lymphocyte ,Drug Resistance, Neoplasm ,T(11/19)(Q23,P13.3) ,Immunology ,Proportional Hazards Model ,Neoplastic Stem Cell ,Cohort Studie ,Chromosomes, Human, Pair 19 ,Transcription Factors ,transplantation - Abstract
To assess the clinical heterogeneity among patients with acute lymphoblastic leukemia (ALL) and various 11q23 abnormalities, we analyzed data on 497 infants, children and young adults treated between 1983 and 1995 by 11 cooperative groups and single institutions. The substantial sample size allowed separate analyses according to age younger or older than 12 months for the various cytogenetic subsets. Infants with t(4;11) ALL had an especially dismal prognosis when their disease was characterized by a poor early response to prednisone (P=0.0005 for overall comparison; 5-year event-free survival (EFS), 0 vs 23+/-+/-12% s.e. for those with good response), or age less than 3 months (P=0.0003, 5-year EFS, 5+/-+/-5% vs 23.4+/-+/-4% for those over 3 months). A poor prednisone response also appeared to confer a worse outcome for older children with t(4;11) ALL. Hematopoietic stem cell transplantation failed to improve outcome in either age group. Among patients with t(11;19) ALL, those with a T-lineage immunophenotype, who were all over 1 year of age, had a better outcome than patients over 1 year of age with B-lineage ALL (overall comparison, P=0.065; 5-year EFS, 88+/-+/-13 vs 46+/-14%). In the heterogeneous subgroup with del(11)(q23), National Cancer Institute-Rome risk criteria based on age and leukocyte count had prognostic significance (P=0.04 for overall comparison; 5-year EFS, 64+/-+/-8% (high risk) vs 83+/-+/-6% (standard risk)). This study illustrates the marked clinical heterogeneity among and within subgroups of infants or older children with ALL and specific 11q23 abnormalities, and identifies patients at particularly high risk of failure who may benefit from innovative therapy.
- Published
- 2003
16. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial
- Author
-
J J Shuster, L. Munoz, Donald H. Mahoney, Bruce M. Camitta, Stuart Toledano, Naomi J. Winick, G. Kiefer, Jeanette Pullen, C P Steuber, and Stephen J. Lauer
- Subjects
Male ,Cancer Research ,Vincristine ,medicine.medical_specialty ,Adolescent ,Gastroenterology ,law.invention ,Randomized controlled trial ,law ,Prednisone ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Acute lymphocytic leukemia ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Child ,Mercaptopurine ,business.industry ,Brain ,Combination chemotherapy ,Hematology ,medicine.disease ,Surgery ,Regimen ,Methotrexate ,Oncology ,Child, Preschool ,Female ,business ,medicine.drug - Abstract
A prospective, randomized multicenter study was performed to evaluate the relative efficacy of two different concepts for early intensive therapy in a randomized trial of children with B-precursor acute lymphoblastic leukemia (ALL) at high risk (HR) for relapse. Four hundred and ninety eligible children with HR-ALL were randomized on the Pediatric Oncology Group (POG) 9006 phase III trial between 7 January 1991 and 12 January 1994. After prednisone (PDN), vincristine (VCR), asparaginase (ASP) and daunorubicin (DNR) induction, 470 patients received either 12 intensive parenteral treatments of intermediate dose (1 g/m2 each) methotrexate (MTX) and mercaptopurine (MP) over 24 weeks (regimen A) or 12 intensive course of alternating myelosuppressive drug combinations given over 30 weeks (regimen B). These drug combinations included MTX/MP, teniposide (VM-26)/cytosine arabinoside (AC) and VCR/PDN/DNR/AC/ASP. Central nervous system (CNS) prophylaxis was age-adjusted triple intrathecal chemotherapy. Patients with CNS disease at diagnosis were treated with craniospinal irradiation after the intensive phase. Continuation was standard doses of MTX and MP for 2 years. This trial was closed early because of an apparent early difference favoring regimen B. Results show that 470 patients achieved remission (97%). Two hundred and thirty two were randomized to regimen A and 238 to regimen B. The estimated 4-year event-free survival (EFS) for patients treated with regimen A is 61.6 % (s.e. = 3.3%) and with regimen B is 69.4% (s.e. = 3.1%), P = 0.091. Toxicities were more frequent on regimen B. In conclusion, for children with B-precursor ALL at high risk to relapse, early intensification with myelosuppressive combination chemotherapy was more toxic but produced no significant difference in EFS when compared to those treated with parenteral methotrexate and mercaptopurine.
- Published
- 2001
17. Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia
- Author
-
Michael D. Amylon, Bee Ching Ding, Jeanette Pullen, Teah L. Witt, Yaddanapudi Ravindranath, Bradley H Pollock, Larry H. Matherly, Sanjay J. Shah, Daniel S. Moore, and Jeffrey W. Taub
- Subjects
Mutation ,biology ,Tumor suppressor gene ,Retinoblastoma protein ,Hematology ,Cell cycle ,medicine.disease_cause ,Molecular biology ,Blot ,Complementary DNA ,Dihydrofolate reductase ,biology.protein ,medicine ,Gene - Abstract
The downstream effects of p15 and p16 gene deletions and loss of transcripts on dihydrofolate reductase (DHFR) were examined in 63 B-precursor (BP) acute lymphoblastic leukaemia (ALL) samples. p15 and/or p16 gene deletions were seen in 6% and 8%, respectively, of BP-ALL samples; however, losses of p15 and/or p16 transcripts were seen in 26 out of 63 (41%) samples. Loss of p15 transcripts (36.5%) exceeded that for p16 (17.5%). For the 26 BP-ALLs that lacked p15 and/or p16 transcripts, only six (23%) exhibited low levels of DHFR by flow cytometry assay with Pt430, a fluorescent anti-folate. Conversely, 18 out of 37 (49%) BP-ALL samples with intact p15 and/or p16 genes and transcripts showed low levels of DHFR (P = 0.04). In p15- and p16-null K562 cells transfected with a tetracycline-inducible p15 cDNA construct, induction of p15 transcripts and protein was accompanied by decreased growth rates, decreased S-phase fraction, decreased retinoblastoma protein phosphorylation, and markedly reduced levels of DHFR transcripts and protein. Collectively, our results suggest that losses of p15 and/or p16 gene expression result in elevated levels of DHFR in BP-ALL in children. However, additional downstream factors undoubtedly also contribute to elevated levels of this enzyme target.
- Published
- 2001
18. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group report of 343 cases
- Author
-
D. Jeanette Pullen, Michael D. Amylon, Jonathan J. Shuster, Bruce M. Camitta, Michael J. Borowitz, Michael P. Link, Julie A. Katz, Nancy R. Schneider, and Andrew J. Carroll
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,Derivative chromosome ,Immunology ,Cytogenetics ,Aneuploidy ,Chromosome ,Karyotype ,Chromosomal translocation ,Cell Biology ,Hematology ,Biology ,medicine.disease ,Biochemistry ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,Survival rate - Abstract
To further define the cytogenetic differences between B-cell lineage (B-lineage) acute lymphoblastic leukemia (ALL) and T-cell lineage ALL (T-ALL) and to determine the prognostic value of cytogenetics in childhood T-ALL, the blast cell karyotypes of 343 cases of pediatric T-ALL, the largest series reported to date, were evaluated. Cytogenetics were performed in a single central laboratory, and the children were treated using a single Pediatric Oncology Group protocol. Clear differences between the karyotypic characteristics of B-lineage ALL and T-ALL were confirmed. This study suggests that there may be survival differences associated with some T-ALL blast cell karyotypes. Better survival is associated with only normal karyotypes and with t(10;14) (translocation of chromosomes 10 and 14); worse survival is associated with the presence of any derivative chromosome. Two new recurring chromosome aberrations previously not reported in T-ALL were found: del(1)(p22) and t(8;12)(q13;p13). Ten aberrations found in this series, which were reported only once previously in T-ALL, can now be considered recurring abnormalities in T-ALL. All 12 of these new recurring aberrations are targets for discovery and characterization of new genes that are important in T-cell development and leukemogenesis.
- Published
- 2000
19. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study
- Author
-
Bruce M. Camitta, J J Shuster, Jeanette Pullen, Michael E. Harris, Frederick G. Behm, V. J. Land, Michael J. Borowitz, and Andrew J. Carroll
- Subjects
Adult ,Male ,Antimetabolites, Antineoplastic ,Cancer Research ,medicine.medical_specialty ,Asparaginase ,Adolescent ,medicine.drug_class ,medicine.medical_treatment ,Gastroenterology ,Antimetabolite ,Disease-Free Survival ,chemistry.chemical_compound ,Double-Blind Method ,Maintenance therapy ,Acute lymphocytic leukemia ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Child ,Chemotherapy ,business.industry ,Cytarabine ,Infant ,Hematology ,medicine.disease ,Burkitt Lymphoma ,Surgery ,Regimen ,Methotrexate ,Treatment Outcome ,Oncology ,chemistry ,Child, Preschool ,Female ,business ,medicine.drug - Abstract
Between May 1987 and January 1991, 1354 patients, 1-21 years old, with standard or poor prognosis B-lineage acute lymphocytic leukemia were treated on the Pediatric Oncology Group Study 8602. One thousand three hundred and twenty-three patients entered remission and 1051 patients were randomized on day 43 to an intensification regimen containing L-asparaginase and intermediate-dose methotrexate (regimen B) or cytarabine and intermediate dose methotrexate (regimen C). After completion of intensification at week 25, all patients received the same maintenance therapy until 3 years from diagnosis. Overall 5-year continuous complete remission (CCR) for regimen B was 72+/-2% (s.e.) and for regimen C, 73+/-2% (P = 0.72 by log-rank analysis). Significant differences between treatments for CCR, testicular, CNS relapses overall or with regard to phenotype (pre-B vs early pre-B), gender, or race were not detected. During intensification, regimen C had significantly more bacterial infections (P = 0.05) and days spent in the hospital (P < 0.001) compared with regimen B, while regimen B had significantly more allergic reactions (P < 0.0001). No significant differences in CCR were noted between patients with pre-B and early pre-B ALL (P = 0.22 stratified by risk group and treatment). This study was unable to detect statistical difference between asparaginase (regimen B) and cytarabine (regimen C) during the intensification phase of therapy in children with B-lineage acute lymphocytic leukemia.
- Published
- 2000
20. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report
- Author
-
Sharon B. Murphy, Michael D. Amylon, Michael J. Borowitz, Yaddanapudi Ravindranath, Joanne Kurtzberg, J J Shuster, Bruce M. Camitta, Molly Schwenn, Julio C. Barredo, Michael P. Link, Jeanette Pullen, and Joseph H. Laver
- Subjects
Adult ,Central Nervous System ,Male ,Risk ,Oncology ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Adolescent ,Cyclophosphamide ,medicine.medical_treatment ,Neutropenia ,Disease-Free Survival ,Cohort Studies ,Leukemic Infiltration ,Prednisone ,Acute lymphocytic leukemia ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Child ,Childhood Acute Lymphoblastic Leukemia ,Injections, Spinal ,Podophyllotoxin ,Teniposide ,Chemotherapy ,business.industry ,Remission Induction ,Cytarabine ,Infant ,Hematology ,Prognosis ,medicine.disease ,Combined Modality Therapy ,Surgery ,Methotrexate ,Treatment Outcome ,Child, Preschool ,Female ,Cranial Irradiation ,business ,medicine.drug - Abstract
Contemporary chemotherapy has significantly improved event-free survival among patients with T cell-lineage acute lymphoblastic leukemia (T-ALL). Unlike B-precursor ALL, most investigators are still using cranial radiation (CRT) and are hesitant to rely solely on intrathecal therapy for T-ALL. In this study we assessed the effects of CRT upon event-free survival and central nervous system (CNS) relapses in a cohort of children with high risk features of T cell leukemia. In a series of six consecutive studies (1987-1995) patients were non-randomly assigned their CNS prophylaxis per individual protocol. These protocols were based on POG 8704 which relied on rotating drug combinations (cytarabine/cyclophosphamide, teniposide/Ara-C, and vincristine/doxorubicin/6-MP/prednisone) postinduction. Modifications such as high-dose cytarabine, intermediate-dose methotrexate, and the addition of G-CSF, were designed to give higher CNS drug levels (decreasing the need for CRT), to eliminate epidophyllotoxin (decreasing the risk of secondary leukemia), and to reduce therapy-related neutropenia (pilot studies POG 9086, 9295, 9296, 9297, 9398). All patients included in this analysis qualified for POG high risk criteria, WBC >50000/mm3 and/or CNS leukemia. Patients without CNS involvement received 16 doses of age-adjusted triple intra-thecal therapy (TIT = hydrocortisone, MTX, and cytarabine) whereas patients with CNS disease received three more doses of TIT during induction and consolidation. Patients who received CRT were treated with 2400 cGy (POG 8704) or 1800 cGy (POG 9086 and 9295). CNS therapy included CRT in 144 patients while the remaining 78 patients received no radiation by original protocol design. There were 155 males and 57 females with a median age of 8.2 years. The median WBC for the CRT+ and CRT- patients were 186000/mm3 and 200000/mm3, respectively. CNS involvement at diagnosis was seen in 16% of the CRT+ and 23% of the CRT- groups. The complete continuous remission rate (CCR) was not significantly different for the irradiated vs. non-irradiated groups (P = 0.46). The 3-year event-free survival was 65% (s.e. 6%) and 63% (s.e. 4%) for the non-irradiated vs. the radiated group. However, the 3-year CNS relapse rate was significantly higher amongst patients who did not receive CRT; 18% (s.e. 5%) vs. 7% (s.e. 3%) in the irradiated group (P = 0.012). Our analysis in a non-randomized setting, suggests that CRT did not significantly correlate with event-free survival but omitting it had an adverse effect on the CNS involvement at the time of relapse.
- Published
- 2000
21. Modelling cure rates using the Gompertz model with covariate information
- Author
-
Peter W. Gieser, Jonathan J. Shuster, Jeanette Pullen, Myron Chang, and P.V. Rao
- Subjects
Statistics and Probability ,Cure rate ,Epidemiology ,Estimation theory ,Quantitative Biology::Tissues and Organs ,Physics::Medical Physics ,Treatment outcome ,Gompertz function ,Linear model ,Regression analysis ,Extended model ,Statistics ,Covariate ,Econometrics ,Mathematics - Abstract
We extend the modified Gompertz hazard function, first used by Cantor and Shuster for estimation of cure rates from pediatric clinical trials, by including covariate effects. The extended model provides a convenient method for estimation of the cure rate as a function of treatments and covariates.
- Published
- 1998
22. Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group
- Author
-
Jeanette Pullen, S.M. Davies, Susan Molleran Lee, Joyce Villanueva, Ashok Kumar, Alexandra H. Filipovich, Tiffany A. Zamzow, Parinda A. Mehta, Meenakshi Devidas, James Elliott, and Y Zewge
- Subjects
Pore Forming Cytotoxic Proteins ,Cancer Research ,Biology ,Polymerase Chain Reaction ,Article ,Acute lymphocytic leukemia ,Genotype ,medicine ,Humans ,Cytotoxic T cell ,Child ,Allele frequency ,Childhood Acute Lymphoblastic Leukemia ,DNA Primers ,Acute leukemia ,Membrane Glycoproteins ,Polymorphism, Genetic ,Base Sequence ,Perforin ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Burkitt Lymphoma ,Genotype frequency ,Oncology ,Immunology ,biology.protein - Abstract
Perforin plays a key role in the cytotoxicity of natural killer and cytotoxic T cells. Genetic mutations in the perforin gene (PRF1) give rise to approximately 30% cases of familial hemophagocytic lymphohistiocytosis. A frequent polymorphism, A91V (C to T transition at position 272), may impair processing of perforin protein to the active form, and has been suggested to increase susceptibility to childhood acute lymphoblastic leukemia (ALL). To investigate the role of A91V in ALL, we genotyped 2272 children with de novo ALL registered on the Pediatric Oncology Group ALL Classification study P9900 and 655 normal controls. Allele frequencies in the controls showed a very low frequency of the variant allele in blacks, 0.7% compared to 4% in white controls. In light of this, analysis was restricted to a comparison of white cases and controls only. Overall genotype frequencies were similar in white ALL cases and normal white controls (P = 0.58), indicating that in contrast to the previous report, A91V polymorphism is not associated with increased risk of childhood ALL. PRF1 A91V frequency was significantly increased in children with BCR-ABL positive ALL (24 vs 8.5%; P = 0.0048); however, this observation includes a relatively small number of cases and needs further exploration.
- Published
- 2006
23. Prognostic Significance of Fluorescence Intensity of Surface Marker Expression in Childhood B-Precursor Acute Lymphoblastic Leukemia. A Pediatric Oncology Group Study
- Author
-
Donald H. Mahoney, D. Jeanette Pullen, Bruce M. Camitta, S J Lauer, Jonathan J. Shuster, Michael J. Nash, Michael J. Borowitz, A. Thomas Look, and Andrew J. Carroll
- Subjects
CD20 ,Oncology ,medicine.medical_specialty ,Percentile ,Univariate analysis ,biology ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Intensity (physics) ,Immunophenotyping ,Antigen ,Predictive value of tests ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,biology.protein ,business - Abstract
This report describes the prognostic significance of the intensity of surface membrane antigen expression in a series of 1,231 children older than 1 year with newly diagnosed B-precursor acute lymphoblastic leukemia (ALL) treated on Pediatric Oncology Group (POG) treatment protocols. All patients had dual-color flow cytometric immunophenotyping performed at a central reference laboratory with a standard panel of monoclonal antibodies. The flow cytometers used in the study were calibrated with a standard fluorescence microparticle that permitted conversion of relative fluorescence channels to standard units of mean equivalents of soluble fluorochrome (MESF). In univariate analysis, fluorescence intensity of CD45 and CD20 was significantly associated with event-free survival (EFS), whereas other markers showed no significant correlation with outcome. Patients whose blasts were greater than the 75th percentile of intensity for CD45 (corresponding to 18,000 MESF units with CD45-FITC, or about 8% of the intensity of normal lymphocytes) fared significantly worse than those with lower-density CD45, and those whose blasts were greater than the 25th percentile of intensity for CD20 (corresponding to 17,900 MESF units with CD20-PE) had a poorer EFS. The intensity of both CD45 and CD20 was independently correlated with outcome. There was no significant correlation between intensity of expression of either antigen and traditional clinical risk factors, ploidy, or t(9; 22) or t(1; 19). All patients with t(4; 11) had CD45 intensity greater than the 75th percentile, but CD45 intensity retained its prognostic significance after adjusting for t(4; 11). In multivariate analysis, both CD45 intensity greater than the 75th percentile and CD20 intensity greater than the 25th percentile were significantly correlated with poor outcome independently of previously reported poor prognostic factors including National Cancer Institute (NCI) risk group, ploidy, trisomies of 4 and 10, and adverse translocations including t(1; 19), t(9; 22), and t(4; 11). We conclude that in childhood B-precursor ALL, the intensity of expression of CD20 and CD45 provides prognostic information not available from simple consideration of antigen expression as positive or negative, and adds to that obtained from traditional clinical and biologic risk factors.
- Published
- 1997
24. Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions
- Author
-
Ayse Batova, Michael D. Amylon, Alice L. Yu, Bradley H Pollock, Thai Vu, John Yu, Jeanette Pullen, and Mitchell B. Diccianni
- Subjects
Heterozygote ,Cancer Research ,medicine.medical_specialty ,Lymphoblastic Leukemia ,T cell ,Cell Cycle Proteins ,Biology ,Gastroenterology ,Disease-Free Survival ,Recurrence ,White blood cell ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Point Mutation ,Clinical significance ,Cyclin-Dependent Kinase Inhibitor p16 ,Germ-Line Mutation ,Cyclin-Dependent Kinase Inhibitor p15 ,P16 Gene Deletion ,Tumor Suppressor Proteins ,Incidence (epidemiology) ,Homozygote ,Single-strand conformation polymorphism ,Hematology ,Genes, p53 ,medicine.disease ,medicine.anatomical_structure ,Oncology ,Immunology ,Carrier Proteins ,Gene Deletion - Abstract
p16 Alterations were detected in >60% of 103 primary T-ALL samples. In paired diagnosis-relapse patient samples, 80% of the relapse samples with p16 deletion were deleted at diagnosis. When p16 was homozygously deleted, p15 gene alterations were found in 72% of the diagnosis T-ALL patient samples, increasing significantly to 100% at relapse. Alterations of p18 were not detected. No clinical significance of p15/p16 gene deletion in diagnosis T-ALL was found with respect to white blood cell (WBC) count, incidence of mediastinal mass, rate of relapse, duration of first remission or event-free survival. In relapse T-ALL, however, patients with p16 deletion experienced a significantly shorter duration of post-relapse survival, demonstrating that p16 deletion is clinically significant in T-ALL.
- Published
- 1997
25. Case-Control Study Suggests a Favorable Impact of TEL Rearrangement in Patients With B-Lineage Acute Lymphoblastic Leukemia Treated With Antimetabolite-Based Therapy: A Pediatric Oncology Group Study
- Author
-
D. Jeanette Pullen, Jeffrey E. Rubnitz, Michael P. Link, Vita J. Land, Jonathan J. Shuster, Ching-Hon Pui, Bruce M. Camitta, James R. Downing, and Frederick G. Behm
- Subjects
Oncology ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.drug_class ,medicine.medical_treatment ,Immunology ,Case-control study ,Retrospective cohort study ,Cell Biology ,Hematology ,Gene rearrangement ,medicine.disease ,Biochemistry ,Antimetabolite ,Germline ,El Niño ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,Internal medicine ,Medicine ,business - Abstract
TEL gene rearrangement is the most common genetic lesion in pediatric acute lymphoblastic leukemia (ALL), occurring in about 25% of B-lineage cases. We previously showed that, among patients treated on St Jude protocols, TEL rearrangement independently conferred an excellent prognosis. To extend these results to patients treated with antimetabolite-based therapy, we performed Southern blot analysis to determine the TEL gene status of 104 cases of B-lineage ALL treated on Pediatric Oncology Group 8602, matched on age, gender, and leukocyte count. There were 52 failures among the 77 patients with germline TEL, compared with only 8 failures among 27 patients in the rearranged group. Based on a two-sided logistic regression analysis, stratified for age (subdivided at 10 years), leukocyte count (subdivided at 50,000), and gender, the estimated odds of failing by 4 years in the germline TEL group is 5.4 times that of the rearranged TEL group, with 95% confidence from 1.9 to 15.6, two-sided P = .0009. Thus, the presence of a rearranged TEL gene is also associated with an improved survival among patients treated with antimetabolite-based therapy. Our results indicate that all newly diagnosed ALL patients should be screened for TEL gene rearrangements and suggest that these patients are candidates for less intensive therapy.
- Published
- 1997
26. Desmoplastic Infantile Gangliogliomas
- Author
-
Roy D. Elterman, Peter C. Burger, Robert A. Sanford, Patricia K. Duffner, Larry E. Kun, Michael E. Cohen, Paul L. Martin, Jeanette Pullen, Andrew D. Parent, Jeffrey P. Krischer, Marc E. Horowitz, and Patricia A. Aronin
- Subjects
Male ,medicine.medical_specialty ,Gliosarcoma ,Malignant meningioma ,Fibrosarcoma ,medicine.medical_treatment ,Brain tumor ,Mitosis ,Ganglioglioma ,Antineoplastic Combined Chemotherapy Protocols ,Glial Fibrillary Acidic Protein ,Biomarkers, Tumor ,Meningeal Neoplasms ,medicine ,Humans ,Neoplasm Staging ,Brain Neoplasms ,business.industry ,Brain ,Infant ,medicine.disease ,Debulking ,Combined Modality Therapy ,Desmoplasia ,Surgery ,Radiation therapy ,Neurology (clinical) ,medicine.symptom ,Glioblastoma ,Meningioma ,business ,Craniotomy ,Follow-Up Studies ,Anaplastic astrocytoma - Abstract
Desmoplastic infantile gangliogliomas are massive cystic tumors, typically occurring in the cerebral hemispheres of infants. They are remarkable pathologically for a prominent desmoplasia and, in some cases, for a cellular mitotically active component that can be readily interpreted as a malignant neoplasm. Four children less than 1 year of age were diagnosed with desmoplastic infantile gangliogliomas in the Pediatric Oncology Group infant brain tumor study (Protocol number 8633). All had been diagnosed by their respective institutions as having malignant tumors, i.e., Grade III astrocytoma, malignant meningioma, leptomeningeal fibrosarcoma, and gliosarcoma. All had increased intracranial pressure, and two had seizures. The tumors were extremely large, with one measuring 12 x 9 x 9 cm. None had evidence of metastatic disease. One patient had a gross total resection, and the other three had debulking procedures. All four children were treated with chemotherapy (cyclophosphamide, vincristine, cisplatinum, etoposide) for periods ranging from 12 to 24 months. Of those with postoperative measurable disease, one child had a complete response, one a partial response, and one had stable disease at the conclusion of chemotherapy. No child received radiation therapy. All children are alive with progression-free survivals after diagnosis of more than 36, 42, 48, and 60 months, respectively. Although desmoplastic infantile gangliomas are rare, recognition of this tumor type is essential because, despite their massive size and pathologically malignant appearance, they may have a relatively benign clinical course. If total surgical resection can be achieved, further therapy may not be indicated. In those patients in whom residual disease is present, chemotherapy appears to be an effective form of therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1994
27. Desmoplastic Infantile Gangliogliomas
- Author
-
Larry E. Kun, Paul L. Martin, Andrew D. Parent, Patricia K. Duffner, Jeanette Pullen, Patricia A. Aronin, Peter C. Burger, Robert A. Sanford, Roy D. Elterman, Jeffrey P. Krischer, Michael E. Cohen, and Marc E. Horowitz
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Complete remission ,medicine.disease ,Dermatology ,Ganglioglioma ,Meningioma ,Radiation therapy ,Partial response ,medicine ,Pediatric oncology ,Surgery ,Neurology (clinical) ,business ,Anaplastic astrocytoma - Published
- 1994
28. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study
- Author
-
Donald H. Mahoney, Michael L. Graham, Stephen J. Lauer, Jeanette Pullen, Brigid G. Leventhal, Curt I. Civin, Stuart E. Adair, Barton A. Kamen, James T. Casper, C. Philip Steuber, Jonathan J. Shuster, Geri Kiefer, and Bruce M. Camitta
- Subjects
Cancer Research ,Asparaginase ,medicine.medical_specialty ,Vincristine ,Chemotherapy ,business.industry ,medicine.medical_treatment ,medicine.disease ,Mercaptopurine ,Surgery ,chemistry.chemical_compound ,Oncology ,chemistry ,Prednisone ,Internal medicine ,Acute lymphocytic leukemia ,Medicine ,business ,Childhood Acute Lymphoblastic Leukemia ,Teniposide ,medicine.drug - Abstract
Background To prevent drug resistance, the authors designed a protocol that featured early intensive rotating drug pairs as part of the therapy for acute lymphoblastic leukemia (ALL). Methods After prednisone, vincristine, asparaginase, and daunorubicin induction, 12 intensive treatments (ABACABACABAC) were given in 30 weeks: A--intermediate-dose methotrexate (IDMTX) plus intermediate-dose mercaptopurine (MP); B--cytosine arabinoside (AC) plus daunorubicin (DNR); C--AC plus teniposide (VM-26). Triple intrathecal chemotherapy (AC, MTX, and hydrocortisone) was given for central nervous system (CNS) prophylaxis. Continuation therapy consisted of weekly MTX and daily MP until 2.5 years of continuous complete remission had been achieved. Results Seventy-four children (age range, 1-19 years) at high risk of relapse were treated. Of 55 with B-lineage (early pre-B, pre-B) ALL, 24 have failed (2 induction failures, 2 deaths from infection, and 20 relapses). The event-free survival (EFS) rate at 4 years was 55.5% (standard error [SE] +/- 7.7%). Of 19 patients with T-cell ALL, 12 have failed (2 induction failures and 10 relapses). The EFS rate at 4 years was 32.6% (SE +/- 26.8%). Toxicities were significantly more common after AC and DNR or AC and VM-26 than IDMTX and MP. There were no toxicity-related deaths during intensive treatments. Conclusion Early intensive rotating therapy is tolerable and warrants consideration for additional trials of patients with high-risk, B-lineage ALL.
- Published
- 1993
29. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study
- Author
-
J J Shuster, W M Crist, Lawrence S. Frankel, James M. Boyett, Michael E. Harris, J van Eys, L Backstrom, Jeanette Pullen, R. Iyer, and Vita J. Land
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Hydrocortisone ,medicine.medical_treatment ,Central Nervous System Diseases ,Leukemic Infiltration ,Risk Factors ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Acute lymphocytic leukemia ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Asparaginase ,Humans ,B Acute Lymphoblastic Leukemia ,Cyclophosphamide ,Injections, Spinal ,Acute leukemia ,Chemotherapy ,Dose-Response Relationship, Drug ,Mercaptopurine ,business.industry ,Cytarabine ,medicine.disease ,Surgery ,Regimen ,Methotrexate ,Vincristine ,Chemoprophylaxis ,Prednisone ,business ,medicine.drug - Abstract
PURPOSE The Pediatric Oncology Group (POG) acute leukemia in childhood (ALinC) 13 study tested two treatment regimens that used different CNS chemoprophylaxis for children older than 12 months with non-T, non-B acute lymphoblastic leukemia (ALL) and with no demonstrable CNS disease at diagnosis. PATIENTS AND METHODS With the first regimen, standard (S), six injections of triple intrathecal chemotherapy (TIC), consisting of methotrexate (MTX), hydrocortisone (HC), and cytarabine (ara-C), were administered during intensification treatment and at every-8-week intervals throughout the maintenance phase for 17 additional doses. The second regimen, standard and MTX pulses (SAM), also specified six TICs during intensification, but substituted every-8-week pulses of intermediate-dose parenteral methotrexate (IDM; 1 g/m2) for the 17 maintenance TIC injections, with a low-dose intrathecal (IT) MTX boost administered with the first four maintenance IDM pulses. Otherwise, systemic therapy on regimen SAM was identical to regimen S. There were 1,152 patients randomized to the S and SAM regimens after stratification by risk group (age/leukocyte count) and immunophenotype. RESULTS The 5-year probabilities (+/- SE) of an isolated CNS relapse were regimen S: good risk (n = 381), 2.8% +/- 1.3%; poor risk (n = 196), 7.7% +/- 3.2%; good + poor risk (n = 577), 4.7% +/- 1.5%; regimen SAM: good risk (n = 388), 9.6% +/- 2.2%; poor risk (n = 187), 12.7% +/- 4.2%; good + poor risk (n = 575), 10.9% +/- 2.2%. In poor-risk patients, approximately one third of the isolated CNS relapses occurred before preventive CNS therapy was begun at week 9. Hence, regimen S has provided better CNS preventive therapy for both good- and poor-risk patients (P < .001 overall). The difference is statistically significant for good-risk patients (P < .001), but not for poor-risk patients (P = .20). Neither treatment has shown a significant advantage in terms of general outcome. CONCLUSION TIC injections extended throughout the intensification and maintenance periods are superior to IDM pulses for prevention of CNS leukemia. Our results with TIC seem comparable with those achieved with other contemporary methods of CNS preventative therapy. Thus, extended TIC affords a reasonable alternative to CNS irradiation plus upfront IT MTX for patients with B-progenitor ALL.
- Published
- 1993
30. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906
- Author
-
W Paul, Bowman, Eric L, Larsen, Meenakshi, Devidas, Stephen B, Linda, Laurie, Blach, Andrew J, Carroll, William L, Carroll, D Jeanette, Pullen, Jonathan, Shuster, Cheryl L, Willman, Naomi, Winick, Bruce M, Camitta, Stephen P, Hunger, and Michael J, Borowitz
- Subjects
Male ,Neoplasm, Residual ,Adolescent ,Mercaptopurine ,Daunorubicin ,Cytarabine ,Infant ,Kaplan-Meier Estimate ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Dexamethasone ,Article ,Methotrexate ,Treatment Outcome ,Risk Factors ,Vincristine ,Child, Preschool ,Antineoplastic Combined Chemotherapy Protocols ,Asparaginase ,Humans ,Prednisone ,Female ,Child ,Thioguanine ,Cyclophosphamide - Abstract
The augmented BFM regimen improves outcome for children with NCI high acute lymphoblastic leukemia (ALL). Patient age, sex, and presenting white blood cell count (WBC) can be used to identify a subset of approximately 12% of children with B-precursor ALL that had a 5-year continuous complete remission (CCR) rate of only about 50% on earlier Pediatric Oncology Group (POG) trials.Children's Oncology Group trial P9906 evaluated a modified augmented BFM regimen in 267 patients with particularly high risk B-precursor ALL. Minimal residual disease (MRD) was assessed in blood at day 8 and in marrow at day 29 of induction and correlated with outcome.The 5-year CCR probability for patients in P9906 was significantly better than that observed for similar patients on POG trials 8602/9006 (62.2 ± 3.7% vs. 50.6 ± 2.4%; P = 0.0007) but similar to POG 9406 (63.5 ± 2.4%; P = 0.81). Interim analysis showed poor central nervous system (CNS) control, especially in patients with initial WBC ≥ 100,000/microliter. Day 29 marrow MRD positive (≥ 0.01%) vs. negative patients had 5 year CCR rates of 37.1 ± 7.4% vs. 72.6 ± 4.3%; day 8 blood MRD positive vs. negative patients had 5 year CCR rates of 57.1 ± 4.6% vs.83.6 ± 6.3%. End induction marrow MRD predicted marrow but not CNS relapse. In multivariate analysis, day 29 MRD0.01%, initial WBC ≥ 100,000/µl, male gender, and day 8 blood MRD0.01% were significant prognostic factors.Augmented BFM therapy improved outcome for children with higher risk ALL. Day 8 blood and day 29 marrow MRD were strong prognostic factors in these patients.
- Published
- 2010
31. t(2;14)(p13;q32): A recurring abnormality in lymphocytic leukemia
- Author
-
Jeanette Pullen, Michael D. Amylon, Frederick G. Behm, Vita J. Land, Andrew J. Carroll, Michael J. Borowitz, Michael P. Link, and Michael S. Watson
- Subjects
Cancer Research ,medicine.medical_specialty ,Chromosomal translocation ,Karyotype ,Biology ,medicine.disease ,Gastroenterology ,Leukemia ,Immunophenotyping ,Internal medicine ,Acute lymphocytic leukemia ,Immunology ,Genetics ,Chromosome abnormality ,medicine ,Abnormality ,Molecular Biology ,Chromosome 12 - Abstract
Chromosome banding studies of 1,411 children with newly diagnosed acute lymphocytic leukemia (ALL) identified two patients with the t(2;14)(p13;q32) chromosome abnormality and a third patient with a complex three-way translocation involving the same breakpoints on chromosomes 2 and 14 but also involving chromosome 12 at band q11. The three cases demonstrated variability of immunophenotypes: one was a T-cell ALL, and two were early pre-B ALLs. All three patients achieved complete remissions and have remained in remission for 14-19 months.
- Published
- 1992
32. Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia
- Author
-
Kiyoshi Takatsuki, Akihiro Shimosaka, Jorge A. Ortega, Vita J. Land, Teresa J. Vietti, Hiroyuki Tsuchiya, Susan R. Wiersma, Michael J. Schell, Gaston K. Rivera, William M. Crist, Masahiko Watanabe, Kenneth I. Weinberg, Ichiro Matsuda, Eugene Sobel, Jonathan J. Shuster, David R. Head, Susana C. Raimondi, Michael J. Borowitz, Ching-Hon Pui, Norio Asou, Frederick G. Behm, C. Philip Steuber, and D. Jeanette Pullen
- Subjects
business.industry ,Cancer research ,Medicine ,General Medicine ,business ,Childhood Acute Lymphoblastic Leukemia ,Myeloid antigen - Published
- 1991
33. Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study
- Author
-
Jonathan J. Shuster, Sabine Kohler, Jeanette Pullen, Michael J. Borowitz, Amos Kedar, Michael P. Link, William M. Crist, Alan Homans, Vita J. Land, Carolyn Russo, Michael D. Amylon, and Andrew J. Carroll
- Subjects
Chromosome 7 (human) ,Oncology ,medicine.medical_specialty ,Monosomy ,Pathology ,Immunology ,Chromosomal translocation ,Cell Biology ,Hematology ,Biology ,Philadelphia chromosome ,medicine.disease ,Biochemistry ,Leukemia ,medicine.anatomical_structure ,Internal medicine ,medicine ,Bone marrow ,Childhood Acute Lymphoblastic Leukemia ,Chronic myelogenous leukemia - Abstract
During an 8-year period, 3,638 children from institutions of the Pediatric Oncology Group (POG) were diagnosed with acute lymphoblastic leukemia (ALL). Fifty-seven patients had Philadelphia chromosome- positive (Ph1) ALL. Blast cells obtained at diagnosis from 13 of these 57 cases (23%) were also found to have partial or complete monosomy 7 (- 7). This subgroup of children with Ph1/-7 ALL was comprised primarily of older males with early B-lineage ALL. Bone marrow specimens from six Ph1/-7 patients were studied further using the polymerase chain reaction and primers that flank the ALL, and chronic myelogenous leukemia breakpoints to determine the molecular characteristic of the 9;22 translocation. Rearrangements were detected in RNA from bone marrow and/or peripheral blood cells of six patients, although four were in hematologic remission at the time of the analysis. Five cases showed the ALL breakpoint, while one child with Ph1/-7 showed the chronic myelogenous leukemia breakpoint. The induction failure rate was much higher in this subgroup (31%) as compared with Ph1-negative cases, and the projected duration of event-free survival reflected the aggressive nature of this subgroup because no children are projected to remain in remission at 2 years. ALL with both the 9;22 translocation and -7 appears to represent a unique and previously undescribed subgroup of childhood ALL associated with a particularly adverse outcome. Leukemic transformation in such patients may involve the interaction of a dominant oncogene (Ph1) and a tumor suppressor gene (- 7).
- Published
- 1991
34. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and down's syndrome. A pediatric oncology group study
- Author
-
Aly Abdel-Mageed, James M. Boyett, Margaret P. Sullivan, Lawrence S. Frankel, William M. Crist, Jeanette Pullen, Jan Van Eys, Abdelsalam H. Ragab, Jonathan J. Shuster, and Michael J. Borowitz
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Proportional hazards model ,Incidence (epidemiology) ,Hepatosplenomegaly ,medicine.disease ,Immunophenotyping ,Oncology ,Acute lymphocytic leukemia ,Internal medicine ,Immunology ,Toxicity ,Cohort ,Medicine ,medicine.symptom ,Risk factor ,business - Abstract
Of 2947 children with acute lymphocytic leukemia (ALL), treated during three consecutive studies of the Pediatric Oncology Group (1974-1986), 52 (1.8%) had Down's Syndrome (DS). Comparison of clinical and laboratory characteristics showed no significant differences in leukocyte count, racial distribution, sex ratio, platelet count, incidence of mediastinal mass, lymphadenopathy or hepatosplenomegaly, or percentage of blood or bone marrow blasts for children with ALL with or without Down's Syndrome (DS-ALL or NDS-ALL, respectively). However, children with DS-ALL were slightly older at the time of presentation and had higher hemoglobin values. The relative frequency of each major immunophenotype (early pre-B, pre-B, T, or B) was also comparable for patients with or without DS. For this report, treatment regimens were categorized as either conventional (no consolidation therapy) or intensive. Cox regression analysis revealed that the presence of DS, a higher leukocyte count, black race, or age older than 10 years was independently associated with a poorer event-free survival (EFS) for children treated with conventional chemotherapy. However, for the cohort of children who received intensive chemotherapy, DS was no longer an independent risk factor. In fact, event-free survival (EFS) was markedly improved to a level comparable with that observed in the children diagnosed as having NDS-ALL. On the other hand, serious toxicity, requiring interruption of treatment, was significantly more frequent in the intensively treated children with DS compared with similarly treated patients with NDS-ALL, although deaths resulting from toxicity occurred infrequently.
- Published
- 1991
35. A pilot study of intermediate‐dose methotrexate and cytosine arabinoside, 'Spread‐out' or 'Up‐front,' in continuation therapy for childhood non‐T, non‐B acute lymphoblastic leukemia a pediatric oncology group study
- Author
-
Donald Pinkel, Vita J. Land, Yaddanapudi Ravindranath, Martin L. Brecher, Robert S. Wimmer, Robert A. Krance, Edward M. Newman, Jonathan J. Shuster, Michael B. Harris, Jeanette Pullen, and William M. Crist
- Subjects
Cancer Research ,medicine.medical_specialty ,Group study ,business.industry ,Incidence (epidemiology) ,Neutropenia ,medicine.disease ,Gastroenterology ,Surgery ,chemistry.chemical_compound ,Oncology ,chemistry ,Internal medicine ,Toxicity ,medicine ,Pediatric oncology ,heterocyclic compounds ,Methotrexate ,B Acute Lymphoblastic Leukemia ,skin and connective tissue diseases ,business ,Cytosine ,medicine.drug - Abstract
One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of standard continuation therapy. The dose and sequence of MTX/Ara-C administration were based on a preclinical model that demonstrated synergism between MTX and Ara-C. Poor-risk patients (n = 49) were assigned to "up-front" therapy, in which the MTX/Ara-C courses were administered during the initial 15 weeks of remission. Standard-risk patients (n = 57) were assigned to "spread-out" therapy, in which the MTX/Ara-C courses were interspersed at 12-week intervals within continuation treatment. Toxicity after intermediate-dose MTX/Ara-C, principally neutropenia and fever, was judged significant but manageable. Unexpectedly, the incidence of fever and neutropenia less than 500/mm3 was greater after "spread-out" therapy (38%) than after "up-front" therapy (6%). At 4 years, the Kaplan-Meier estimate of event-free survival (EFS) is 71% (+/- 7%) for standard-risk patients and 53% (+/- 8%) for poor-risk patients. The results of this pilot study support the use of intermediate-dose MTX/Ara-C in additional studies.
- Published
- 1991
36. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases [see comments]
- Author
-
Vita J. Land, Frederick G. Behm, Lawrence S. Frankel, David R. Head, C. Philip Steuber, Michael J. Borowitz, Jonathan J. Shuster, Andrew J. Carroll, William M. Crist, D. Jeanette Pullen, Susana C. Raimondi, and Ching-Hon Pui
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Immunology ,Chromosomal translocation ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Infant Acute Lymphoblastic Leukemia ,Immunophenotyping ,El Niño ,Antigen ,Acute lymphocytic leukemia ,Internal medicine ,Medicine ,Hyperdiploidy ,business ,Childhood Acute Lymphoblastic Leukemia - Abstract
The t(4;11)(q21;q23) chromosomal abnormality was identified in 40 (2%) of 1,986 children with newly diagnosed acute lymphoblastic leukemia (ALL). This translocation was associated with female sex (63%), age less than 1 year (60%), hyperleukocytosis (median leukocyte count, 156.5 x 10(9)/L), CD10-/CD19+ B-precursor cell immunophenotype, and myeloid-associated antigen (CD15) expression (63%). Nearly all cases had at least some CD24- blast cells. The CD10-/CD15%/CD19+/CD24/+ phenotype was found in 20 of the 32 t(4;11) cases tested. None of the 40 cases had the cytogenetic finding of hyperdiploidy greater than 50, which is a favorable prognostic feature. For clinical comparison, the t(4;11) cases were divided into three groups according to age at diagnosis: less than 1 year (n = 24), 1 to 9 years (n = 8), and greater than or equal to 10 years (n = 8). Compared with older patients, infants were more likely to have initial central nervous system leukemia (P = .05) and less likely to have pre-B-cell ALL (P = .05). Complete continuous remission has been maintained in only 7 of 24 infants and 2 of 8 patients aged greater than or equal to 10 years, in contrast to 7 of 8 children in the intermediate age group (P = .048). These findings suggest that the t(4;11) is an adverse prognostic feature in these two age groups.
- Published
- 1991
37. High-Dose Cyclophosphamide-High-Dose Methotrexate with Coordinated Intrathecal Therapy for Advanced Nonlymphoblastic Lymphoma of Childhood
- Author
-
Eva Hvizdala, Martin L. Brecher, Jonathan J. Shuster, Jeanette Pullen, Costan W. Berard, Teresa J. Vietti, William M. Crist, Abdel Ragab, Irma Ramirez, and Margaret P. Sullivan
- Subjects
Male ,medicine.medical_specialty ,Vincristine ,Adolescent ,Hydrocortisone ,Cyclophosphamide ,medicine.medical_treatment ,Leucovorin ,Gastroenterology ,Prednisone ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Life Tables ,Child ,Injections, Spinal ,Chemotherapy ,business.industry ,Lymphoma, Non-Hodgkin ,Remission Induction ,Cytarabine ,Large-cell lymphoma ,Infant ,Hematology ,medicine.disease ,Lymphoma ,Surgery ,Survival Rate ,Regimen ,Methotrexate ,Treatment Outcome ,Oncology ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Female ,business ,medicine.drug - Abstract
The Pediatric Oncology Group (POG) investigated a high-dose cyclophosphamide (CPM) high-dose methotrexate (MTX) regimen to determine therapeutic efficacy in confirmed advanced nonlymphoblastic non-Hodgkin's lymphoma (NHL) (stages III and IV) and B-cell acute lymphatic leukemia (B-ALL) in children. Another goal was to determine the comparative effectiveness of shortened maintenance treatment (2 versus 6 courses) in the study population. Systemic induction therapy included vincristine, prednisone, cyclophosphamide, and intermediate-dose MTX with leucovorin rescue. Superimposed intrathecal (IT) therapy included cytosine arabinoside for 2 successive days followed on day 3 by MTX. Intrathecal MTX was given 3 times during induction. At the end of induction, 2 days of triple (hydrocortisone, MTX, and cytosine arabinoside) therapy were given intrathecally (TIT). All patients then received a consolidation course of 4 doses of TIT, 2 doses of cyclophosphamide, and 4 more courses of vincristine and MTX with leucovorin rescue. Patients were then randomized to receive either 2 or 6 cycles of vincristine plus MTX with leucovorin rescue. The TIT was given with each cycle. Complete response rates by histology and Murphy stage (1) were as follows: undifferentiated lymphoma (DUL) stage III, 84/105 (80%): stage IV, 5/12 (42%); and other NHL [primarily large cell lymphoma (LCL)] stage III, 21/28 (75%); stage IV, 2/3 (67%). Event-free survival (EFS) at greater than 2 years was similar for patients with DUL and LCL, i.e., 65 and 61%, respectively. No significant difference in outcome was noted between patient groups receiving 2 or 6 maintenance treatments (p = .76). Treatment was notable for its modest toxicity following the early change to single-dose CPM therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1991
38. Prospective Analysis of TEL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: a Children's Oncology Group Study
- Author
-
Jeffrey E. Rubnitz, David Wichlan, Meenakshi Devidas, Jeanette Pullen, Stephen B. Linda, Allen R. Chauvenet, Stephen P. Hunger, Bruce M. Camitta, Jonathan J. Shuster, Joanne Kurtzberg, Ching-Hon Pui, and Beverly Bell
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Time Factors ,Adolescent ,Oncogene Proteins, Fusion ,Kaplan-Meier Estimate ,Risk Assessment ,Article ,Disease-Free Survival ,Sex Factors ,Bone Marrow ,hemic and lymphatic diseases ,Acute lymphocytic leukemia ,Internal medicine ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,medicine ,Humans ,Prospective Studies ,Prospective cohort study ,Child ,Childhood Acute Lymphoblastic Leukemia ,Survival rate ,Proportional Hazards Models ,Gene Rearrangement ,business.industry ,Proportional hazards model ,Gene Expression Regulation, Leukemic ,Cancer ,Infant ,Gene rearrangement ,medicine.disease ,Prognosis ,United States ,Survival Rate ,Treatment Outcome ,El Niño ,Child, Preschool ,Core Binding Factor Alpha 2 Subunit ,Female ,business - Abstract
Purpose To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL). Patients and Methods TEL gene status was determined for 926 patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 16 trials and patients were observed for a median time of 8 years. Results Rearrangements of the TEL gene were detected in 244 patients (26%). The estimated 5-year event-free survival rate (± SE) for patients with TEL rearrangements was 86% ± 2%, compared with 72% ± 2% for those with germline TEL (P < .0001). TEL rearrangements were associated with a superior outcome among patients with standard-risk ALL, high-risk ALL, and rapid early responses to therapy. In a multivariate analysis that included risk group, sex, and day 15 marrow status, TEL status was an independent predictor of outcome (P = .0002). Conclusion We conclude that TEL gene status should be incorporated into risk classification schemes and suggest that patients who have standard-risk features, the TEL-AML1 fusion, and rapid early responses to therapy, should be treated with antimetabolite-based therapy designed to maintain their high cure rates and avoid late effects.
- Published
- 2008
39. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
- Author
-
Stephen B. Linda, Naomi J. Winick, David S. Viswanatha, W. Paul Bowman, Bruce M. Camitta, Paul L. Martin, Meenakshi Devidas, Cheryl L. Willman, Stephen P. Hunger, William L. Carroll, Andrew J. Carroll, D. Jeanette Pullen, and Michael J. Borowitz
- Subjects
Oncology ,medicine.medical_specialty ,Prognostic variable ,Neoplasm, Residual ,Oncogene Proteins, Fusion ,Clinical Trials and Observations ,Immunology ,Biochemistry ,Disease-Free Survival ,Bone Marrow ,Recurrence ,Risk Factors ,Internal medicine ,Acute lymphocytic leukemia ,hemic and lymphatic diseases ,Biomarkers, Tumor ,Medicine ,Humans ,Clinical significance ,Child ,Childhood Acute Lymphoblastic Leukemia ,Proportional Hazards Models ,Clinical Trials as Topic ,Hematology ,business.industry ,Proportional hazards model ,Cancer ,Cell Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Prognosis ,Minimal residual disease ,body regions ,Treatment Outcome ,Core Binding Factor Alpha 2 Subunit ,Multivariate Analysis ,business - Abstract
Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed. The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL). The presence of MRD in day-8 blood and day-29 marrow MRD was associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.01% to 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients (59% ± 5% vs 88% ± 1% 5-year EFS). Presence of good prognostic markers TEL-AML1 or trisomies of chromosomes 4 and 10 still provided additional prognostic information, but not in National Cancer Insitute high-risk (NCI HR) patients who were MRD+. The few patients with detectable MRD at end of consolidation fared especially poorly, with only a 43% plus or minus 7% 5-year EFS. Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis. The 12% of patients with all favorable risk factors, including NCI risk group, genetics, and absence of days 8 and 29 MRD, had a 97% plus or minus 1% 5-year EFS with nonintensive therapy. These studies are registered at [www.clinicaltrials.gov][1] as [NCT00005585][2], [NCT00005596][3], and [NCT00005603][4]. [1]: http://www.clinicaltrials.gov [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00005585&atom=%2Fbloodjournal%2F111%2F12%2F5477.atom [3]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00005596&atom=%2Fbloodjournal%2F111%2F12%2F5477.atom [4]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00005603&atom=%2Fbloodjournal%2F111%2F12%2F5477.atom
- Published
- 2008
40. The t(1;14)(p34;q11) is nonrandom and restricted to T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study
- Author
-
Andrew J. Carroll, D. Jeanette Pullen, George R. Buchanan, William M. Crist, Teresa J. Vietti, Robert S. Wimmer, Abdel Ragab, Michael D. Amylon, and Michael P. Link
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,T cell ,Immunology ,Breakpoint ,Cytogenetics ,Chromosomal translocation ,Karyotype ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Leukemia ,Immunophenotyping ,medicine.anatomical_structure ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,business - Abstract
We report the nonrandom occurrence, frequency, and degree of immunophenotype association of the t(1;14)(p34;q11) in children with acute lymphoblastic leukemia (ALL). This chromosomal abnormality occurred in leukemia cells from 5 of 1,630 (0.3%) consecutive children with newly diagnosed ALL who were entered on a single Pediatric Oncology Group classification study (POG 8600) between January 1986 and February 1989. The frequency of the t(1;14) was 3% (5 of 168 cases) in children with T-cell ALL. All five cases had pseudodiploid karyotypes, and in 3 cases the t(1;14) was accompanied by a deletion of the long arm of chromosome 6. This translocation is of special interest because the breakpoint on chromosome 14 in band q11 corresponds to the assigned locus of the T-cell receptor alpha/delta chain gene. All five of our patients and three cases reported previously have had T-cell ALL. These findings, considered together, suggest that this translocation is specific for T-cell ALL and that a gene in the 1p34 region may play an important role in malignant transformation of thymocytes.
- Published
- 1990
41. Favorable prognosis associated with hyperdiploidy in children with acute lymphocytic leukemia correlates with extra chromosome 6. A pediatric oncology group study
- Author
-
Jeanette Pullen, Michael J. Borowitz, John F. Jackson, Richard B. Patterson, Vita J. Land, William M. Crist, B. Brock, David R. Head, and James M. Boyett
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,business.industry ,Cytogenetics ,Aneuploidy ,Karyotype ,Chromosomal translocation ,medicine.disease ,Gastroenterology ,Oncology ,Internal medicine ,Acute lymphocytic leukemia ,medicine ,Hypodiploidy ,Hyperdiploidy ,business ,Survival rate - Abstract
Pretreatment bone marrow cytogenetic studies were included for 1664 patients with acute lymphoblastic leukemia (ALL) accrued to Pediatric Oncology Group (POG) 8035 laboratory classification study from May 1981 through January 1986. There was a significant difference (P = 0.0001) in distribution of stem-line karyotype (normal, hypodiploid, pseudodiploid, or hyperdiploid) among children with early pre-B, pre-B, or T-cell ALL, with early pre-B patients demonstrating a higher proportion of hyperdiploid karyotypes with modal chromosome numbers greater than 51. Cytogenetic classification of 1216 patients with early pre-B or pre-B ALL evaluable for duration of event-free survival (EFS), with median follow-up of 42 months, showed a significant prolongation of five-year EFS associated with hyperdiploidy greater than 51 (75%; standard error [SE] = 5%) compared with hyperdiploidy 47 to 51 (46%; SE = 7%), hypodiploidy (55%; SE = 11%), and pseudodiploidy (45%; SE = 7%) (P = 0.0001). Five-year EFS was intermediate for patients with normal (58%), constitutionally abnormal (66%), or unsuccessful analyses (66%). The breakpoint defining hyperdiploidy associated with better prognosis was best defined as greater than 51 (P = 0.0002). Of 239 children with hyperdiploid karyotypes, analysis of the contribution of each chromosome to EFS duration showed a significant association between improved EFS and additional chromosome(s) six (P = 0.02). Chromosome translocation was associated with shorter EFS (P = 0.0001).
- Published
- 1990
42. Religiosity and coping in mothers of children diagnosed with cancer: an exploratory analysis
- Author
-
Mary Elizabeth Gilbert, Jeanette Pullen, Scott A. Jensen, Lacy McNeil, Linda McComb, and T. David Elkin
- Subjects
Adult ,Male ,Religion and Psychology ,Coping (psychology) ,Health Knowledge, Attitudes, Practice ,Mothers ,Psychology, Child ,Coping behavior ,Nursing Methodology Research ,Pediatrics ,Severity of Illness Index ,Christianity ,Statistics, Nonparametric ,Religiosity ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Neoplasms ,Surveys and Questionnaires ,Adaptation, Psychological ,Humans ,Child ,Depressive symptoms ,Psychiatric Status Rating Scales ,030504 nursing ,Oncology (nursing) ,Depression ,Positive coping ,Religious belief ,Exploratory analysis ,humanities ,Self Care ,030220 oncology & carcinogenesis ,Case-Control Studies ,Female ,0305 other medical science ,Psychology ,Attitude to Health ,Clinical psychology - Abstract
Although several factors related to coping in parents of children diagnosed with cancer have been explored, little is known about their religious beliefs and behavior and its relationship to coping. The purpose of this study was to provide preliminary data on the religious beliefs and behaviors of mothers of children with cancer and the relation to their psychological adjustment. Twenty-seven mothers of children diagnosed with cancer completed several measures of religious beliefs and behaviors as well as the Beck Depression Inventory—II. The sample was highly religious and specifically Christian. Thirty percent of the mothers reported elevated levels of depressive symptoms, and these mothers reported lower levels of religious belief and behavior than the mothers who denied depressive symptoms. These data suggest a relationship between religiosity and positive coping behavior that should continue to be explored.
- Published
- 2007
43. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia
- Author
-
Susana C. Raimondi, Maxine Sutcliffe, R. Ellen Magenis, Warren G. Sanger, Nyla A. Heerema, Peter Van Tuinen, Bruce M. Camitta, Andrew J. Carroll, Loris McGavran, Michael S. Watson, Jeanette Pullen, Shivanand R. Patil, James R. Anderson, Paul S. Gaynon, Linda D. Cooley, Betsy A. Hirsch, Nancy R. Schneider, Jaclyn A. Biegel, Mark J. Pettenati, Diane Roulston, Jonathan J. Shuster, and Kathleen W. Rao
- Subjects
Genetics ,Chromosome Aberrations ,Cancer Research ,Chromosome ,Karyotype ,Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Modal Number ,Pediatric Acute Lymphoblastic Leukemia ,Tetrasomy ,medicine ,Chromosomes, Human ,Cluster Analysis ,Humans ,Hyperdiploidy ,Chromosome 21 ,Child ,Mitosis - Abstract
Children with acute lymphoblastic leukemia (ALL) and high hyperdiploidy (>50 chromosomes) are considered to have a relatively good prognosis. The specific extra chromosomes are not random; extra copies of some chromosomes occur more frequently than those of others. We examined the extra chromosomes present in high hyperdiploid ALL to determine if there were a relation of the specific extra chromosomes and modal number (MN) and if the extra chromosomes present could differentiate high hyperdiploid from near-triploid and near-tetraploid cases. Karyotypes of 2,339 children with ALL and high hyperdiploidy at diagnosis showed a distinct nonrandom sequential pattern of gain for each chromosome as MN increased, with four groups of gain: chromosomes 21, X, 14, 6, 18, 4, 17, and 10 at MN 51-54; chromosomes 8, 5, 11, and 12 at MN 57-60; chromosomes 2, 3, 9,16, and 22 at MN 63-67; chromosomes 1, 7 13, 15, 19, and 20 at MN 68-79, and Y only at MN >or=80. Chromosomes gained at lower MN were retained as the MN increased. High hyperdiploid pediatric ALL results from a single abnormal mitotic division. Our results suggest that the abnormal mitosis involves specific chromosomes dependent on the number of chromosomes aberrantly distributed, raising provocative questions regarding the mitotic mechanism. The patterns of frequencies of tetrasomy of specific chromosomes differs from that of trisomies with the exception of chromosome 21, which is tetrasomic in a high frequency of cases at all MN. These results are consistent with different origins of high hyperdiploidy, near-trisomy, and near-tetrasomy.
- Published
- 2007
44. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG)
- Author
-
Jeffrey E. Rubnitz, Stephen P. Hunger, William L. Carroll, Paul S. Gaynon, Kirk R. Schultz, Meenakshi Devidas, Elizabeth A. Raetz, Harland N. Sather, Nyla A. Heerema, Michael J. Borowitz, Mignon L. Loh, Naomi J. Winick, Andrew J. Carroll, D. Jeanette Pullen, Bruce M. Camitta, and Jonathan J. Shuster
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Pediatrics ,Neoplasm, Residual ,Adolescent ,Clinical Trials and Observations ,Immunology ,Lower risk ,Biochemistry ,Risk Assessment ,Disease-Free Survival ,Internal medicine ,Acute lymphocytic leukemia ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,medicine ,Humans ,Risk factor ,Child ,Retrospective Studies ,Hematology ,business.industry ,Cancer ,Infant ,Retrospective cohort study ,Cell Biology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Classification ,Prognosis ,Minimal residual disease ,Treatment Outcome ,Child, Preschool ,Cytogenetic Analysis ,Female ,Risk assessment ,business ,Algorithms ,Biomarkers - Abstract
The Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG) joined to form the Children's Oncology Group (COG) in 2000. This merger allowed analysis of clinical, biologic, and early response data predictive of event-free survival (EFS) in acute lymphoblastic leukemia (ALL) to develop a new classification system and treatment algorithm. From 11 779 children (age, 1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, n = 4986) and POG (January 1986 to November 1999, n = 6793), we retrospectively analyzed 6238 patients (CCG, 1182; POG, 5056) with informative cytogenetic data. Four risk groups were defined as very high risk (VHR; 5-year EFS, 45% or below), lower risk (5-year EFS, at least 85%), and standard and high risk (those remaining in the respective National Cancer Institute [NCI] risk groups). VHR criteria included extreme hypodiploidy (fewer than 44 chromosomes), t(9;22) and/or BCR/ABL, and induction failure. Lower-risk patients were NCI standard risk with either t(12;21) (TEL/AML1) or simultaneous trisomies of chromosomes 4, 10, and 17. Even with treatment differences, there was high concordance between the CCG and POG analyses. The COG risk classification scheme is being used for division of B-precursor ALL into lower- (27%), standard- (32%), high- (37%), and very-high- (4%) risk groups based on age, white blood cell (WBC) count, cytogenetics, day-14 marrow response, and end induction minimal residual disease (MRD) by flow cytometry in COG trials.
- Published
- 2007
45. Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia
- Author
-
Shirley Hogan, Jitsuda Sitthi-Amorn, Betty Herrington, Jeanette Pullen, Catherine M. Gordon, Tejaswi Koganti, Gail Megason, and Chindo Hicks
- Subjects
Microarray ,business.industry ,DNA repair ,Cancer ,Disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Bioinformatics ,medicine.disease ,lcsh:RC254-282 ,Minimal residual disease ,B-cell acute lymphoblastic leukemia ,body regions ,Granzyme B ,Transcriptome ,Oncology ,hemic and lymphatic diseases ,minimal residual disease ,gene expression ,Cancer research ,Medicine ,business ,Gene ,Original Research - Abstract
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related death in children and adolescents. Minimal residual disease (MRD) is a strong, independent prognostic factor. The objective of this study was to identify molecular signatures distinguishing patients with positive MRD from those with negative MRD in different subtypes of ALL, and to identify molecular networks and biological pathways deregulated in response to positive MRD at day 46. We compared gene expression levels between patients with positive MRD and negative MRD in each subtype to identify differentially expressed genes. Hierarchical clustering was applied to determine their functional relationships. We identified subtype-specific gene signatures distinguishing patients with positive MRD from those with negative MRD. We identified the genes involved in cell cycle, apoptosis, transport, and DNA repair. We also identified molecular networks and biological pathways dysregulated in response to positive MRD, including Granzyme B, B-cell receptor, and PI3K signaling pathways.
- Published
- 2015
46. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study
- Author
-
Amy L. Billett, William L. Carroll, Mary Anne H. Marymont, Stephen J. Lauer, Julio C. Barredo, Naomi J. Winick, Bruce M. Camitta, Jeanette Pullen, A. Kim Ritchey, and Meenakshi Devidas
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,ThioTEPA ,Asymptomatic ,Gastroenterology ,Drug Administration Schedule ,Acute lymphocytic leukemia ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Child ,Survival analysis ,Acute leukemia ,Chemotherapy ,business.industry ,Brain Neoplasms ,Cancer ,Infant ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Combined Modality Therapy ,Survival Analysis ,Surgery ,medicine.anatomical_structure ,Treatment Outcome ,Oncology ,Child, Preschool ,Female ,Bone marrow ,medicine.symptom ,Cranial Irradiation ,business ,medicine.drug - Abstract
Purpose Prognosis and outcome of children with isolated CNS relapse of acute lymphoblastic leukemia (ALL) has depended on duration of first complete remission (CR1). This study intensified systemic therapy by delaying CNS radiation for 12 months and tailored CNS radiation by CR1 duration. Patients and Methods Seventy-six children with first isolated CNS relapse of ALL were treated with systemic chemotherapy that effectively penetrates into the CSF and intrathecal chemotherapy for 12 months. Patients with CR1 of less than 18 months received craniospinal radiation (24 Gy cranial/15 Gy spinal), whereas those with CR1 of 18 months or more received cranial radiation only (18 Gy), followed by maintenance chemotherapy. Additionally, asymptomatic patients were enrolled in a thiotepa up-front therapeutic window. Results Seventy-four (97.4%) of 76 eligible patients achieved a second remission. Overall 4-year event-free survival (EFS) for the 71 precursor B-cell patients was 70.1% ± 5.8%. CR1 duration and National Cancer Institute (NCI; National Institutes of Health, Bethesda, MD) risk group at initial diagnosis predicted outcome. Patients with CR1 of less than 18 months and 18 months or more had a 4-year EFS of 51.6% ± 11.3% and 77.7% ± 6.4% (P = .027), respectively. NCI high- versus standard-risk 4-year EFS was 51.4% ± 10.8% and 80.2% ± 6.3% (P = .0018), respectively. A significant difference in EFS between standard risk/CR1 of at least 18 months and both high risk/CR1 of less than 18 months and high risk/CR1 of at least 18 months groups was detected (P = .0068 and .0314, respectively). Response rate to thiotepa was 78%. Most relapses involved the bone marrow, and three second malignancies were reported. Conclusion Twelve months of intensive systemic chemotherapy with reduced dose cranial radiation (18 Gy) is highly effective for children with isolated CNS relapse and CR1 of 18 months or more. Novel strategies are needed for patients with CR1 of less than 18 months.
- Published
- 2006
47. 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner
- Author
-
Mitchell B, Diccianni, John, Yu, Gerda, Meppelink, Marten, de Vries, Lien, Shao, Sigrun, Gebauer, Hsien, Shih, William, Roberts, Neil P, Kilcoin, Jeanette, Pullen, Dennis A, Carson, and Alice L, Yu
- Subjects
Treatment Outcome ,Aminoacridines ,Genes, p16 ,Proto-Oncogene Proteins ,Cyclin-Dependent Kinase 4 ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,DNA ,Enzyme Inhibitors ,Genes, p53 ,Prognosis ,Cyclin-Dependent Kinases ,DNA Damage - Abstract
In T-cell Acute Lymphocytic Leukemia (T-ALL), the inhibitors of cyclin-dependent kinases (CDK) 4 and 6, p16 and p15, are inactivated almost universally at the DNA, RNA and protein levels. This suggests that CDK-targeting may be an effective therapeutic approach for T-ALL and other cancers. In this study, we tested 3 inhibitors of CDK4, 3-aminothioacridone (3-ATA), thioacridone (TA), and oxindole, for their effects on DNA synthesis and viability in primary T-ALL. Each compound was an effective inhibitor, with overall IC(50)s in similar ranges. In colony formation assay, leukemic cells were approximately 10-fold more sensitive to 3-ATA than normal bone marrow cells. When sorted by G1 protein status of T-ALL, p16(+), p15(+) or pRb(-) samples were significantly less sensitive to 3-ATA and TA, but not to oxindole, than p16(-), p15(-) or pRb(+) samples. There was no relationship of sensitivity with ARF expression. Despite their in vitro function as inhibitors of CDK4, 3-ATA did not inhibit pRb phosphorylation or cause G1 arrest, but did cause DNA damage and result in the induction and phosphorylation of p53. We conclude that 3-ATA efficacy can be predicted by p16 status in T-ALL, but the mechanism of action may be distinct from their in vitro ability to regulate CDK4 kinase activity
- Published
- 2005
48. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome
- Author
-
M.F. Auclerc, W. A. Kamps, Hansjörg Riehm, G. E. Janka-Schaub, Paul S. Gaynon, Jochen Harbott, Bruce M. Camitta, Maria Grazia Valsecchi, C H Pui, Stefania Galimberti, Susana C. Raimondi, Andrew J. Carroll, Harland Sather, Christine J. Harrison, Susan M. Richards, Jeanette Pullen, Lewis B. Silverman, Nyla A. Heerema, Martin Schrappe, Maurizio Aricò, V. Conter, Giuseppe Basso, J J Shuster, Heerema, N, Harbott, J, Galimberti, S, Camitta, B, Gaynon, P, Janka Schaub, G, Kamps, W, Basso, G, Pui, C, Schrappe, M, Auclerc, M, Carroll, A, Conter, V, Harrison, C, Pullen, J, Raimondi, S, Richards, S, Riehm, H, Sather, H, Shuster, J, Silverman, L, and Valsecchi, M
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,TERM FOLLOW-UP ,Biology ,Philadelphia chromosome ,Disease-Free Survival ,Genetic Heterogeneity ,CHILDRENS CANCER GROUP ,PEDIATRIC-ONCOLOGY-GROUP ,POOR-PROGNOSIS ,Internal medicine ,Acute lymphocytic leukemia ,PROGNOSTIC-SIGNIFICANCE ,medicine ,Humans ,Philadelphia Chromosome ,CHRONIC MYELOID-LEUKEMIA ,CLINICAL-SIGNIFICANCE ,Child ,Childhood Acute Lymphoblastic Leukemia ,ADVERSE RISK ,Chromosome 7 (human) ,Chromosome Aberrations ,Acute leukemia ,Likelihood Functions ,Philadelphia Chromosome Positive ,Cytogenetics ,Karyotype ,Chromosome Breakage ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Prognosis ,GENE ,Survival Analysis ,TRIALS ,Treatment Outcome ,childhood acute lymphoblastic leukemia ,Immunology ,Cytogenetic Analysis ,secondary abnormalities ,Female ,secondary abnormalitie ,Chromosome Deletion ,prognosi - Abstract
Additional chromosomal aberrations occur frequently in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) of childhood. The treatment outcome of these patients is heterogeneous. This study assessed whether such clinical heterogeneity could be partially explained by the presence and characteristics of additional chromosomal abnormalities. Cytogenetic descriptions were available for 249 of 326 children with Ph+ ALL, diagnosed and treated by 10 different study groups/large single institutions from 1986 to 1996. Secondary aberrations were present in 61% of the cases. Chromosomes 9, 22, 7, 14, and 8 were most frequently abnormal. Most (93%) karyotypes were unbalanced. Three main cytogenetic subgroups were identified: no secondary aberrations, gain of a second Ph and/or >50 chromosomes, or loss of chromosome 7, 7p, and/or 9p, while other secondary aberrations were grouped as combinations of gain and loss or others. Of the three main cytogenetic subgroups, the loss group had the worst event-free survival (P=0.124) and disease-free survival (P=0.013). However, statistical significance was not maintained when adjusted for other prognostic factors and treatment. Karyotypic analysis is valuable in subsets of patients identified by molecular screening, to assess the role of additional chromosomal abnormalities and their correlation with clinical heterogeneity, with possible therapeutic implications.
- Published
- 2004
49. Minimax two-stage-designs with applications to tissue banking case-control studies
- Author
-
Bruce M. Camitta, Michael P. Link, Jonathan J. Shuster, Fredrick Behm, and Jeanette Pullen
- Subjects
Statistics and Probability ,Research design ,Leukemia ,Operations research ,Epidemiology ,Numerical Analysis, Computer-Assisted ,Variance (accounting) ,Tissue Banks ,Minimax ,Term (time) ,Clinical trial ,Sample size determination ,Research Design ,Case-Control Studies ,Sample Size ,Prior probability ,Biomarkers, Tumor ,Humans ,Computer Simulation ,Child ,Type I and type II errors - Abstract
'Tissue banks' are created, at least in part, to help medical scientists learn about disease biology on the basis of samples provided by patients on treatment protocols that were competed years earlier. The bank inventory consists of precious non-renewable patient material (such as frozen diagnostic blood or bone marrow), which can be linked to both clinical data and long term follow-up information. Case-control studies, where cases represent clinical failures and controls clinical successes, are ideal for rapidly learning if a laboratory marker might have prognostic significance. While group sequential (multi-stage) methods are widely used in clinical trials, they have rarely been applied in case-control studies. Further, unlike clinical trials where safety and efficiency may actually be in conflict, case-control studies can focus on efficiency. Hence, minimizing the expected sample size is a desirable goal in such a setting. Since the true effect size is never known, and since no prior distribution can be postulated for the effect size, we have opted for the minimax solution. A strategy is developed to determine amongst all two-stage designs with given type I and type II errors, the one for which the maximum expected sample size is minimized. The user is provided with simple tables, whereby one can determine everything necessary to conduct the study from the corresponding calculation for a single-stage design. A matched pair example is given where the suggested design can be modified, to obtain a superior 'two-plus' stage design. The basic idea is to conduct the first stage as planned, but use the estimate of variance to redesign the study, without using the estimate of effect size in the redesign.
- Published
- 2002
50. Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemic cells predicts treatment outcome in children: a Pediatric Oncology Group study
- Author
-
Michael P. Link, Richard S. Larson, Jill J. Sweatman, Jeanette Pullen, Stuart S. Winter, Bruce M. Camitta, J J Shuster, and Amylon
- Subjects
Oncology ,Adult ,Cancer Research ,medicine.medical_specialty ,Stromal cell ,Adolescent ,Cell Survival ,Bone Marrow Cells ,Cell Line ,Leukocyte Count ,Stroma ,Acute lymphocytic leukemia ,Internal medicine ,medicine ,Tumor Cells, Cultured ,Humans ,Leukemia-Lymphoma, Adult T-Cell ,Cell Lineage ,Prospective cohort study ,Child ,business.industry ,Lymphoblast ,Infant ,Hematology ,medicine.disease ,Coculture Techniques ,medicine.anatomical_structure ,Treatment Outcome ,El Niño ,Case-Control Studies ,Child, Preschool ,Immunology ,Bone marrow ,Neoplasm Recurrence, Local ,Stromal Cells ,business ,Ex vivo - Abstract
Significant predictors of treatment outcome are poorly defined for patients with T-lineage acute lymphoblastic leukemia (T-ALL). A high WBC at diagnosis, which has traditionally been a predictor of poor response in T-ALL, has considerably weakened prognostic significance in the face of modern, more intensive chemotherapy. To test the hypothesis that bone marrow stroma-supported leukemic cell recovery might identify children at high risk for relapse, we measured the ex vivo recovery of T-ALL lymphoblasts from 29 newly diagnosed patients using a stromal cell co-culture assay. In all cases the T-ALL lymphoblasts showed an increase in recovery of T-ALL cells (RTC), ranging from 4 to 343%, in comparison to samples maintained without stroma. Since we were blinded to patient outcome in this case-control study, we then correlated patient outcome with RTC. The RTC for 18 patients in complete continuous remission (CCR) for greater than 4 years was stochastically larger than for the 11 patients who eventually relapsed (P = 0.011, by the two-sided Wilcoxon test). Furthermore, 100% of patients with an RTC of more than 26% had a CCR greater than 4 years while 78% of the patients with an RTC of less than 25% relapsed within 4 years. This is the first report to show that higher lymphoblast recovery may predict a more favorable outcome for children with T-ALL. A prospective study is needed to test whether stroma-supported leukemic cell recovery might serve as a basis for assigning risk-adjusted therapy.
- Published
- 2001
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.